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We have previously demonstrated a significant association between human herpesvirus 
8 (HHV-8) seroprevalence among men with prostate cancer in the Caribbean island of 
Tobago compared to cancer free men.  HHV-8 DNA has been detected in semen and 
prostatic tissues in some, but not all reports. I have performed immunohistochemistry 
(IHC) on prostate tissues from HHV-8 seropositive men from the United States and 
Tobago with prostate cancer for the expression of viral proteins and determined if 
expression of these proteins are associated with increased inflammation.  My results 
demonstrate the presence of viral proteins in prostates from seropositive men and 
among tissues expressing these viral proteins, there is increased inflammation as 
measured by macrophage infiltrate.  I have also looked for the presence of 
polymorphisms in several genes previously associated with increased risk of prostate 
cancer to determine if there was a genetic link with the greater risk for prostate cancer 
in Tobago.  We have found single nucleotide polymorphism in the IL-6 gp130 signaling 
receptor that is associated with increased prostate cancer risk among HHV-8 
seropositive men.    The public health relevance observed by these results suggests an 
interaction between HHV-8 infection, increased inflammation and genetic 
polymorphisms resulting in increased prostate cancer risk.    I hypothesize that HHV-8 is 
a cofactor for prostate cancer in Tobago by establishing a chronic infection which leads 
to chronic inflammation and ultimately prostate cancer. 
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1.0 Chapter One:  Introduction 
1.1 Prostate Cancer 
Prostate cancer is the most common cancer among men in the United States and is 
second to lung cancer as a cause of cancer death 1.   Each year there are 186,320 
estimated new cases of prostate cancer, which is equal to 6.5 new cases per 100,000 
men a year 1.  Prostate cancer is the leading site of new cancer cases, at 25% of all 
cancers found in men 1. The annual incidence of prostate cancer has increased by more 
than 30% over the last 25 years, primarily due to earlier diagnosis following serum PSA 
(prostate specific antigen) screening, while the mortality rate has increased around 14% 
over the last 60 years2.  It has been said that if a man lives to be 80 he will die with 
prostate cancer and not from it.  Supporting this idea is the statistic that one in 30 men 
will develop prostate cancer in their life time; and one is six of those men will develop 
invasive prostate cancer 1 .   
1.1.1 Signs and Symptoms 
 
In the early stages of prostate cancer, often times no symptoms occur.  In the later, 
more advanced stages of the cancer, men may experience problems with urine flow 
such as interrupted, weak, or inability to urinate 2.   
1 
 
1.1.2 Risk Factors 
Known risk factors include a family history of prostate cancer, age, and ethnicity.  
Proposed co-factors for prostate cancer include prostatic inflammation, diet, and 
sexually transmitted agents 3.   Risk of prostate cancer is not uniform among the 
different races.  Prostate cancer is most prevalent in African Americans than either 
Caucasians or Asians, with some cancer registries reporting a 30-fold or greater 
difference between African Americans and Asians 1,4.  This increased risk seen in those 
of African descent is not limited to the United States.  In a recent study from the 
Caribbean nation of Trinidad & Tobago, the prevalence of screening-detected prostate 
cancer was 3-fold higher among Tobago men of African descent compared to US 
Caucasian men 5,6.  Our lab has previously reported an elevated seroprevalence of 
human herpesvirus 8 (HHV-8) among men from Tobago with prostate cancer compared 
to age-matched controls (P=0.003, OR 2.24, 95% C.I. 1.29-3.90) 7.  This finding lends 
support to an infectious agent co-factor for prostate cancer. 
While the reason for the population differences in prostate cancer incidence is not 
known, several studies have suggested a genetic factor 3.  A number of prostate cancer 
candidate genes have been investigated 11, but candidate gene polymorphisms which 
consistently explain ethnic differences in risk have yet to be identified. 
1.1.2.1 Inflammation and Prostate Cancer 
A positive association between prostatic inflammation and onset of cancer has been 
reported 8.  The results of epidemiologic studies have demonstrated correlations 
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between prostatitis and sexually transmitted diseases with increased prostate cancer 
risk 9.  It has been estimated that up to 15% of all malignancies diagnosed worldwide 
can be traced to infections 10.  A  single infectious agent has not been identified leading 
Nelson and colleagues to speculate that host immune responses to infections in the 
prostate (rather than the agent itself) may serve as the risk factor for prostate cancer 9.  
Viruses have the ability to alter the microenvironment in which they are present, 
therefore it is plausible that inflammation associated with a chronic viral infection may 
contribute to the development of prostate cancer 11.   However, the results from studies 
investigating several human viruses, notably herpes simplex, cytomegalovirus, and 
papillomaviruses have not supported this role 12.  In addition, some, but not all, studies 
on anti-inflammatory drugs have suggested a potential protective effect on prostate 
cancer development 13-15.  The idea that chronic inflammation may trigger cancer by 
providing additional insults to pre-malignant cells is shared among many cancer types.  
Recent studies depicting chronic inflammatory environments where leukocyte 
recruitment is persistent show that stimulation  through the release from  tumor-
associated macrophages of factors such as cytokines and chemokines promote 
angiogenesis, tumor growth and metastasis 8,10,16,17.   More recently, tumor associated 
macrophage density has been associated with poor clinical outcome among many 
different cancers 18.  Lissbrant and colleagues reported the association of increased 
tumor associated macrophages in prostate cancer patients with shorter survival time 19.  
An example of the model of chronic infection is cervical carcinoma where a chronic 
inflammatory response, due to the presence of human papilloma virus, promotes 
epithelial cell proliferation, tissue remodeling and angiogenesis which, over time, leads 
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to invasive carcinoma 16.  Thus the presence of a chronic prostatic infection resulting in 
chronic inflammation may serve as a co-factor for prostate cancer development. 
1.1.2.2 IL-6 and Prostate Cancer 
Interleukin-6 (IL-6) is a cytokine involved in many cellular functions including 
proliferation, apoptosis, angiogenesis, and differentiation 20.  The major source of IL-6 is 
macrophages, but it can be produced by multiple cell types including, T and B 
lymphocytes, fibroblasts, endothelial cells, keratinocytes, and mast cells 21.   IL-6 has a 
molecular weight of approximately 23kDa 20.    It is comprised of 212 amino acids as a 
propeptide and 190 amino acids as a mature protein 22.  IL-6 signalling produces an 
autocrine feedback loop in cells that it acts upon. 
IL-6 binding consists of two receptors:  a binding receptor, gp80 (also known as IL-6Rα), 
and a signaling receptor, gp130 20.  IL-6 binds to a soluble form of gp80 with low 
affinity23.   Glycoprotein 80 has a single transmembrane span and a short cytoplasmic 
domain.  The extracellular domains of gp80 are an immunoglobulin like domain and a 
common structural domain of hematopoietic growth factor receptor domain, conserved 
cysteine residues and the WS (tryptophan and serine) sequence motif 24.      The 
gp80:IL-6 complex is tetrameric, two gp80 molecules and two IL-6 molecules 24.  
Binding of the gp80 receptor alone does not active IL-6 signaling.  The gp80:IL-6 
complex must then bind two gp130 molecules, forming a hexameric complex.  The 
binding to gp130 is required for high affinity 24.   Binding of the gp130 molecules 
activates the Janus kinases, JAK, that phosphorylate gp130.  Phosphorylation of gp130 
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induces activation and translocation of signal tranducers and activators of transcription 
three, STAT-325.   
 Initially most prostate cancers are androgen-dependent and therefore are responsive to 
androgen-ablative therapies26.   Androgen ablation inhibits tumor growth.  Unfortunately, 
most of these cancers re-emerge as more lethal androgen-insensitive cancers.  It has 
been postulated that these androgen-independent cancers evolve when they develop 
the ability to regulate their own cell growth through autocrine pathways 26.   IL-6 has 
been implicated as an important growth factor for prostate cancer acting in autocrine or 
paracrine pathways 27.  After androgen ablation, IL-6 is seen to be elevated along with 
its receptor in organ-confined tumors 21.   It is noteworthy that prostatic cancer cell lines 
that are androgen-dependent (e.g. LNCaP) do not constitutively express hIL-6 while the 
cytokine is expressed in cell lines from androgen-insensitive prostate cancers (e.g. PC3, 
DU-145) 28.  Chronic treatment with exogenous IL-6 leads to a positive feedback loop in 
prostate cancer cells as shown by the cell line LNCaP-IL-6+, a subline of LNCaP, that 
has greater proliferation in the presence of IL-6 29.  In addition, IL-6 has been shown to 
be capable of activating the androgen receptor pathway through the induction of STAT-
3 resulting in the expression of androgen receptor sensitive genes 30,31.  Thus IL-6 may 
act as a growth factor for prostate cancer replacing the requirement for androgen.  
Serum levels of IL-6 have been correlated with prostate cancer disease outcome such 
that higher levels predict poorer outcomes 32,33.  Taken together these studies implicate 
IL-6 as an important mediator of human prostate cancer. 
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1.2  Human Herpesvirus 8 (HHV-8)  
Human herpesvirus 8 (HHV-8), also known as Kaposi’s sarcoma associated 
herpesvirus, is the causative agent of Kaposi’s sarcoma (KS) as well as a rare primary 
effusion lymphoma 34,35.  HHV-8 is the most recently discovered human herpesvirus.  
HHV-8 was first identified in AIDS-KS tissue in 1994 36.  It is a member of the 
lymphotrophic (gamma) herpesviruses; it is a gamma-2 herpesvirus or a radinovirus, to 
be specific 35.  HHV-8 primarily infects endothelial cells and B-lymphocytes 35.  
Transmission of HHV-8 can occur through sexual contact 37,38 as well as non-sexual 
routes 39-41.   
1.2.1 HHV-8 and Associated Cancers 
Human herpesvirus 8 is known to cause Kaposi’s sarcoma, primary effusion lymphoma, 
and some forms of multicentric castleman’s disease 35,42.   
1.2.1.1 Kaposi’s sarcoma 
Kaposi’s sarcoma, KS,  was first described by as a disease of elderly men late in the 
19th century in Europe 35.  It was initially known to be more prevalent in Mediterranean 
areas 35.   Kaposi’s sarcoma is characterized by the classic spindle cell shape (figure 1), 
neo-angiogenesis, inflammation, and edema 43,44.  Four types of Kaposi’s sarcoma have 
been described: classic, endemic, iatrogenic, and epidemic 45. 
Classic KS is also referred to as European, sporadic, or chronic KS.  Kaposi sarcoma is 
primarily seen, 90% of the cases, in males 60 years old or older of the Ashkenazi 
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Jewish or Mediterranean origin 45.  These lesions typically localize to the lower 
extremities and affect the skin 45.   
 
Figure 1: KS Lesion 
This is a Hematoxylin & Eosin (H & E) staining of a KS lesion. The picture was taken at 
400x.  The uniform small spindle cells adjacent to the vessel wall are denoted by an 
arrow. 
 
Endemic KS is mainly seen in Africa.  HHV-8 was prevalent in Africa prior to the HIV 
epidemic which explained the large prevalence of KS seen on the continent 46.  
Endemic KS is divided into two subtypes: the first seen in adults, ages 25-50, and the 
second seen in young children under the age of 1045.  The first subgroup is seen 
primarily in sub-Saharan countries of Africa.   Where KS comprises 17% of all 
neoplasms in adult males and is the second most common cancer in women.  It 
presents with skin involvement and massive edema47.  The second subgroup is seen 
mainly in Bantu children and is characterized by lymphadenopathy that is pronounced in 
the cervical region.  This is a serious condition that often results in death within two 
years of diagnosis47.   
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Iatrogenic KS is typically associated with solid organ transplant recipients.  In the 
context of immunosuppression, as with organ transplants, both primary infection and 
reactivation of HHV-8 becomes a potential concern.  It has been shown that post-
transplant immunosuppression can cause iatrogenic KS to appear 47.  Post-transplant 
KS can cause significant clinical manifestations such as rejection of the transplant which 
can lead to death of the patient.  In a study of 356 post-transplant patients with KS, 40% 
had visceral involvement, and 17% of those with visceral KS died from the tumor 47.   
Epidemic KS, also known as AIDS-associated KS, is  a more aggressive tumor than 
classic KS and can disseminate into the viscera with a greater likelihood of death 48.  
AIDS-associated KS often presents multifocally and more frequently on the upper body 
and head regions 49.  The incidence of KS varies among groups of patients with AIDS, 
21-40% of men having sex with men develop KS while only 1.6% of pediatric AIDS 
cases and 1% of hemophiliac’s develop KS 45.   
1.2.1.2 Primary Effusion Lymphoma 
 Primary effusion lymphoma (PELs) was first identified as a subset of body-cavity-based 
lymphomas and have been shown to contain HHV-8 DNA sequences 50.  The consistent 
presence of HHV-8 in PELs implies an important role for HHV-8 in the pathogenesis of 
this rare lymphoma which accounts for only 4.0% of all AIDS malignancies in AIDS 
patients in the USA 51.  While HHV-8 is always associated with PELs, Epstein-Barr virus 
is only seen variably 52.  PELs characteristically lack a solid component and 
morphologically show immunoblastic and anaplastic large-cell lymphomas with some 
plasma cell differentiation 51.  
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1.2.1.3 Multicentric Castleman’s Disease 
HHV-8 is also linked to another B cell lymphoproliferative disorder called Multicentric 
Castleman’s Disease (MCD), which can be described by generalized lymphadenopathy 
with polyclonal hyperimmunoglobulinemia and high levels of serum IL-6 53 54.  Unlike KS 
and PELs, HHV-8 DNA sequences have only been detected in a subset of MCD 
patients, who are usually co-infected with HIV 54.  MCD presents as B-cells with large 
size and large vesicular nucleus with one or two prominent nucleoli 55.   
1.3 HHV-8 transmission and seroprevalence 
The seroprevalence rates of HHV-8 in the general population vary depending on the 
geographic region.  Seroprevalence in the United States is between 5-10% 56.  HHV-8 
seroprevalence is higher among HIV-seronegative homosexual subjects compared with 
the HIV-seronegative heterosexual population, ranging from 20% to 38% 38,57 58 and is 
even higher in HIV-seropositive homosexual populations, ranging from 30% to as high 
as 48% 56 59 60.  In homosexual men who are seropositive for both HHV-8 and HIV, the 
presence of HHV-8 DNA in peripheral blood mononuclear cells precedes and predicts 
the development of KS 61 41.  Currently virus has been detected in saliva 41 62, and 
occasionally in genital secretions 41 63 64.  These data shows an important role for 
salivary virus transmission.  Other modes of transmission have also been debated as 
some large cohorts of intravenous drug users and highly exposed hemophiliacs did not 
show increased seroprevalence over the general population65.  Other studies, however 
have detected a relationship between seropositivity and the frequency or duration of 
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injection drug use 58.  In the higher-prevalence societies of the Mediterranean Basin and 
Africa, a different epidemiologic pattern occurs.  Infection is equally prevalent in adult 
men and women, and infection begins in childhood, often times by the mother chewing 
the food for the child 66.   Some infections are acquired from contact with infected 
parents, but many infections are acquired by spread from child to child during childhood 
43,67. Following puberty, seroprevalence continues to slowly rise throughout early to mid-
adulthood.  This pattern is currently thought to reflect inefficient heterosexual 
transmission 68,69. 
1.4 HHV-8 Genome and Structure 
The HHV-8 genome is  double–stranded linear DNA of 165 to 170 kilobases (kb) 35 70.  
The genome contains a central unique region of 145 kb, which includes all of the viral 
open reading frames, flanked by a series of highly GC-rich direct terminal repeats 35.   
The HHV-8 virion itself is comprised of an electron dense nucleocapsid that is 
surrounded by a lipid bilayer envelope; in between those two layers is the tegument, a 
proteinaceous region that is highly organized but morphologically unremarkable 35.  
HHV-8 has four major subtypes: A, B, C, and D. Each subtype if found in different 
regions of the globe.  A and C are seen in USA, Asia, Europe, and Middle East 35.  B is 
seen in sub-Saharan Africa, while D is seen in South Asia, Australia, and the Pacific 
Islands 35.   
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1.5 HHV-8 Replication Cycle 
 
As is characteristic of herpesviruses, HHV-8 can establish either a latent, non-
replicating, or a lytic, actively replicating infection.  During latency, the viral genome is 
maintained as a circular episome whose replication is coupled to cellular replication.  
The viral gene products that are expressed during latency are important for maintaining 
the viral genome and for ensuring the survival of an infected population of cells.  No 
infectious virus is produced during latency, but there is a clonal expansion of the 
infected population due to viral episomal replication being coupled to cellular 
replication71.  The cells that support latent replication are at risk for tumor development 
because viral proteins expressed during latency disrupt important regulatory pathways 
within the cell.   HHV-8 latent genes which have wide spread distribution in advanced 
KS lesions are:  latency associated nuclear antigen-1 (LANA-1) (involved in the 
establishment and maintenance of latency), viral-cyclin (a homologue of cellular cyclin 
D), viral-FLICE inhibitory protein (v-FLIP) (involved in blocking/recruiting caspase 8), 
and kaposin which is known to induce tumor formation 71.   v-FLIP is associated with 
anti-apoptotic activity 72, and activation of NF-kB by v-FLIP is associated with prolonged 
survival of HHV-8 infected primary effusion lymphoma cell lines 73.  LANA-1 can 
antagonize p53-mediated apoptosis 71, and v-cyclin can inactivate tumor suppressor Rb 
and cyclin dependent kinase pathway inhibitor p27, thus promoting cell cycle 
progression 74.  LANA-1 and v-FLIP can also induce IL-6 secretion in HHV-8 infected 
cells 75,76.  The kaposin gene also encodes several microRNAs (miRNA), which may 
regulate gene expression by binding to complementary messenger RNAs 77.  Latently 
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infected cells have the potential to shift to lytic replication once the replication 
transactivator (RTA/ORF50) is activated 71.  Lytic replication is accompanied by 
expression of numerous viral proteins needed for making mature virions.  Cells 
undergoing lytic replication are typically not at risk for malignant transformation because 
the host cell is usually destroyed when the replication cascade is complete 78 .  This 
process releases hundreds of viral particles from a single cell 79. Lytic replication is 
critical for transmission to uninfected cells, which includes dissemination to new hosts.  
Infectious virus egress from the cell is often associated with a viral syndrome that 
results from multiple factors, including the altered function of newly infected cells, the 
lysis of infected cells, and the expression of viral gene products such as v-IL-6, and a 
viral-G protein-coupled receptor (v-GPCR), that have systemic and paracrine effects 80. 
1.5.1 Proteins of Interest 
The experiments outlined in this dissertation focus on three viral proteins, LANA-1, 
K8.1, and vIL-6 (viral IL-6).  LANA-1 is used as the latent phase protein, while K8.1 and 
vIL-6 are used as the lytic phase proteins. 
1.5.1.1 LANA-1 
LANA-1 is a widely used as the marker for HHV-8 infection.  The protein is 
approximately 230kDa in size, 81 and  is encoded by open reading frame (ORF) 73 81.    
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1.5.1.2 K8.1 
K8.1 is a late lytic gene that encodes for a glycoprotein that is approximately 36kDa in 
size 82.   K8.1 encodes two transcripts, K8.1A and K8.1B; K8.1A is highly immunogenic 
and is the transcript chosen for these studies83. 
1.5.1.3 vIL-6 (viral Interleukin 6) 
HHV-8 encodes a homologue for IL-6, termed viral IL-6 (vIL-6) which is encoded by 
ORF K2.  The protein has 204 amino acids with a predicted size of 23.4 kD and shares 
24.7% identity with the human IL-6 and 24.9% identity with murine IL-6 84. Comparison 
of the predicted amino acid sequences of vIL-6 and human and mouse IL-6 (hIL-6 and 
mIL-6) shows strong homology to the region of the cellular IL-6 protein involved in 
receptor binding 84. The vIL-6 protein has been shown to be capable of supporting the 
growth of an IL-6-dependent hybridoma cell line, B9, as well as being capable of binding 
to the gp80 receptor, activating the IL-6 signaling cascade 85.   Interestingly, the vIL-6 
protein can also bind to the gp130 homodimer, in the absence of gp80 86.  Thus the vIL-
6 protein can initiate IL-6 signaling without binding to the gp80 receptor.  This would 
permit the vIL-6 protein to trigger signaling in a larger variety of cell types (including 
those that do not express the gp80 receptor, but do express gp130).  It has been 
demonstrated by several laboratories that prostate cells and prostatic cancer cells 
express both gp80 and gp130 87.   Since HHV-8 seropositivity is associated with the 
presence of prostate cancer and the virus encodes a homologue for IL-6 which is 
capable of binding both gp80 and gp130 receptors, I have hypothesized that HHV-8, 
through expression of vIL-6, may mediate either the development or progression of 
prostate cancer. 
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  1.6 HHV-8 Seroprevalence Among Men from Tobago with Prostate Cancer 
Our laboratory recently published a case control study with participants from the 
Caribbean Island of Tobago7.  The study consisted of 138 men from Tobago with 
biopsy-proven prostate cancer (Tobago Cancer).  There were 140 age matched controls 
consisting of men from Tobago with no evidence of prostate cancer (Tobago controls).  
Control men had normal digital rectal exams and PSA values less than 4.0ng/ml.  Also 
included in the study were 174 men from Trinidad with no evidence of prostate cancer 
(Trinidad controls).  The race distribution of the groups were as follows:  Tobagonians 
97% African, where Trinidadians were 90% Asian Indian descent with the remaining 
10% of African descent. 
The study revealed that in HHV-8 seroprevalence being higher among the prostate 
cancer group compared to the corresponding controls (Table 1).  Men with prostate 
cancer were more likely to be HHV-8 seropositive than there age-matched cancer free 
controls (OR 2.24;95% C.I. 1.29-3.90) 7.  
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Table 1  HHV-8 Serological Comparisons  
 
 
Group 
 
HHV-8 
Serology  
(% positive) 
 
 
P* 
 
 
OR (95% C.I.) 
 
Tobago Prostate Cancers 
 
55/138 (39.9) 
 
 
0.003* 
 
 
2.24 (1.29 - 3.90)  
Tobago Controls 
 
32/140 (22.9) 
 
Trinidad Controls** 35/174 (20.1) <0.001**
 
2.63 (1.54 B 4.50)
*       Fisher’s Exact Test 
**     Comparison with Tobago Prostate Cancers 
1.7 HHV-8 infection and gp130 polymorphism in prostate cancer. 
Recent studies in our laboratory discovering the association of HHV-8 infection and 
prostate cancer, which may be mediated by vIL-6 signaling through gp130 led to a 
search of the single nucleotide polymorphism (SNP) database for polymorphism in the 
gp130 gene that may be associated with increased cancer risk.  The gp130 signaling 
receptor is shared among the members of the four helix cytokines including IL-6, IL-11, 
and Oncostatin M 25.  The laboratory of Dr. Robert Ferrell at the University of Pittsburgh, 
Graduate School of Public Health resequenced nine putative SNPs in gp130.  Six 
(rs3730294 4084522, 4865630, 1063560, 4084824 and 10180) were monomorphic in 
24 Tobago samples; one (rs4277867) was minimally informative; and two (rs3730293 
and 3729960) were informative, but in complete linkage disequilibrium.  Rs 3729960, an 
arginine to glycine transition at position R148G in the conserved extracellular ligand 
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binding domain of gp130 was genotyped in 217 cases and 183 controls.  The GG 
genotype was associated with elevated prostate cancer risk, OR=1.5 (95% CI 0.98-
2.32) in logistic regression and both gp130 and HHV-8 seropositivity were 
independently associated with prostate cancer.  Further exploration of the six genotype 
HHV-8 combinations revealed on OR of 3.1 (95% CI 1.2-8.1 p=0.022) for prostate 
cancer in men who are HHV-8 seropositive and have the GG genotype, compared to 
the lowest risk group, who are HHV-8 negative and have the CC genotype (Table 2).  
This effect of gp130 genotype may be mediated through its role in IL-6 signaling in 
inflammation or through its direct role in vIL-6 signaling.   
 
Figure 2: Predicted Protein Secondary Structure of the High and Low Risk Alleles of gp130 
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Table 2. HHV-8 gp130 Interaction 
  Case Non-Case   
HHV8 gp130 N % N % OR 95%CI 
- CC 39 17.9 41 22.4 1.0  
- CG 65 29.9 61 33.3 1.0 0.57-1.73 
- GG 37 17.1 34 18.6 1.2 0.62-2.25 
+ CC 18 8.3 11 6.0 1.5 0.64-3.72 
+ CG 37 17.1 29 15.8 1.3 0.69-2.58 
+ GG 21 9.7 7 3.9 3.1 1.18-8.11 
Total  217  183    
 
 
 
 
 
 
 
 
 
Table 2 shows the HHV-8 gp130 interaction in Tobago.  
1.8 Hypothesis 
The following research focuses on the presence of HHV-8 in the prostate and how 
HHV-8 infection in the prostate results in macrophage infiltration to the infection site.   
As previously stated, increase macrophage infiltrate in the prostate has been associated 
with poorer clinical outcome 8,16,17,18.  Following the model outlined by human papilloma 
virus in cervical carcinoma which results in a chronic inflammatory response due to the 
presence of the virus that over time leads to invasive carcinoma16, it is reasonable to 
look for a chronic prostatic infection resulting in chronic inflammation that may serve as 
a co-factor for prostate cancer development. 
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I believe that,  since HHV-8 has oncogenic potential, can be spread sexually, and has 
been detected in prostate tissue 88, it is a reasonable candidate for an infectious agent 
cofactor for the development of prostate cancer (Figure 3) 
 
Figure 3: HHV-8 as a Co-Factor in the Development of Prostate Cancer.   
HHV-8 infects the cells of the prostate, both lytic (pink cells) and latent (red nuclei) 
infection is present.  The presence of the virus causes an inflammatory response 
(macrophage infiltrate).  The virus sets up a chronic infection leading to a chronic 
inflammation which can lead to benign prostatic hyperplasia or prostate cancer. 
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1.9 Specific Aims 
 
This project is built on previous epidemiological work done by Linda Hoffman, Ph.D.  in 
our laboratory 7. 
1.9.1 Specific Aim 1 
 
Test the hypothesis that HHV-8 is present in the prostates of HHV-8 seropositive men.  
We will test three distinct cohorts:  MACS, Tobago and PUCC. 
I performed immunohistochemistry on normal, non-cancerous prostate tissue of men 
from the MACS (Multicenter AIDS Cohort Study) group.  The MACS cohort will had an 
N=18, 16 seropositive and 2 seronegative.   Serial sections were examined for 
expression of a viral protein expressed during viral latency, the latent nuclear antigen-1 
(LANA-1) and two viral proteins expressed during viral replication (vIL-6 and K8.1).  The 
vIL-6 protein is a viral homologue of the cellular cytokine IL-6 while K8.1 is a viral 
glycoprotein.    
Detection of HHV-8 protein expression in cancerous prostates is also necessary to 
support our hypothesis.  We have preformed IHC on biopsy material and prostatectomy 
sections from men with prostate cancer from the Caribbean nation of Trinidad & 
Tobago.  The Tobago cohort consisted of biopsy subjects N=19, 12 seropositive and 7 
seronegative, and the prostatectomy subjects N=20, 11 seropositive and 9 
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seronegative, each subject had areas of cancer and areas that are cancer-free that 
were stained.  Serial sections were examined for LANA-1 and K8.1.   
 A cohort from the PUCC, Pittsburgh Urologic Cancer Cohort, was also examined for 
expression of the same proteins.  The PUCC cohort had an N=39, 19 seropositive and 
20 seronegative. 
1.9.2 Specific Aim 2 
Test the hypothesis that expression of HHV-8 proteins in prostate tissues is associated 
with increased inflammation.  Inflammation was determined by IHC using antibodies 
directed against CD68, a macrophage marker, and CD20, a B-cell marker.  Differences 
in levels of inflammation will be determined by percent of total cells positive for a 
marker.   This will be done in all three cohorts:  MACS, Tobago, and PUCC. 
1.9.3  Specific Aim 3 
Test the hypothesis that the polymorphism R148G in the gp130 signaling receptor, 
which has been associated with an increase risk of prostate cancer in Tobago, results in 
altered protein properties.  I will characterize cell lines expressing the high and low risk 
gp130 allele (C/C low risk & G/G high risk).  I have obtained 10 cell lines from  Tobago 
men with prostate cancer who have one of the three possible genotypes (3 C/C, 5 C/G, 
2 G/G).  For each cell line determinations will be made on whether the different 
genotypes affect cellular growth in the presence or absence of the gp130 alleles and the 
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cytokines IL-6, IL-11, and OSM.  The effect of exogenous hIL-6 on cell proliferation will 
be tested.   
I will also determine the functional effect of the gp130 polymorphism by determining 
downstream signaling effects.  I will determine the effects of IL-6 on STAT-3 activation 
in the different Tobago cell lines. 
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2.0  Chapter Two:  Detection of HHV-8 in the cells of the Prostate:  MACS Cohort 
Detection of Human Herpesvirus 8 (HHV-8) in Normal Prostates 
 
Jill D. Montgomery1, Lisa P. Jacobson3, Rajiv Dhir2, and Frank J. Jenkins1,2 
 
Published in The Prostate, September 2006 
 
1 Department of Infectious Diseases and Microbiology, University of Pittsburgh, 
Pittsburgh, Pennsylvania 
2 Department of Pathology, University of Pittsburgh, Pittsburgh, Pennsylvania 
3 Department of Epidemiology, The Johns Hopkins School of Public Health, 
Baltimore, Maryland 
 
 
 
*Corresponding Author +1 412 623 3233 (phone), +1 412 623 1119 (fax), 
jenkinsfj@pitt.edu 
 
 
keywords: HHV-8 ; KSHV ; Prostate Cancer ; IHC ; chronic inflammation 
 
 
22
2.1 Preface 
Inflammation has been indicated as a possible co-factor of prostate cancer.  The results 
of epidemiology studies have demonstrated correlations between prostatitis and 
sexually transmitted diseases with increased prostate cancer risk 9.  A single infectious 
agent has not been identified leading to speculation that host immune responses to 
infections in the prostate, rather than the agent itself, may serve as the risk factor for 
prostate cancer.  We wished to test the hypothesis that HHV-8 is present in the 
prostates of seropositive men and that expression of HHV-8 proteins in the prostate 
tissues is associated with increased inflammation.   This cohort is comprised of men 
who died with AIDS, but had histologically proven cancer-free prostates.    We were 
able to show that HHV-8 is present in the prostates of seropositive men, and the 
expression of viral proteins is associated with increased inflammation. 
 
The following manuscript, for which I was first author and performed all experiments 
was published in The Prostate.   
2.2 Abstract 
 
Background: Human herpesvirus 8 (HHV-8) DNA has been detected in semen and 
prostatic tissues in some, but not all reports.  We have analyzed prostate tissues from 
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HHV-8 seropositive men for the expression of viral proteins and determined if 
expression of these proteins are associated with increased inflammation.  Methods: 
Paraffin sections of non-cancerous prostates from HHV-8 seropositive (n=16) and 
seronegative (n=2) men who died with AIDS were screened for expression of three viral 
proteins by immunohistochemistry.  Levels of inflammation were determined by 
expression of CD68 and CD20.  Cellular proliferation was determined by expression of 
Ki67.  Results:  Among the 16 HHV-8 seropositive cases, 68.9% (11/16) (95% C.I.= 
0.41-0.89) were positive for HHV-8 protein expression, while the 2 seronegative patients 
showed no HHV-8 protein expression.  There was increased inflammation among HHV-
8 positive prostates.   Conclusions:  These results demonstrate that HHV-8 is present 
in normal prostates of HIV-infected men and the expression of viral proteins is 
associated with increased localized inflammation.   
2.3 Introduction 
 
Human herpesvirus 8 (HHV-8) is the causative agent of Kaposi’s sarcoma (KS) as well 
as a rare primary effusion lymphoma 35.  Transmission of HHV-8 can occur through 
sexual contact 37,38 suggesting that the virus is present in organs and associated ducts 
of the male reproductive tract such as testes, prostate, urethra, etc.   While viral DNA 
has been found by some laboratories in semen and in both normal and cancerous 
prostate tissues 89-93 these findings are controversial since other laboratories have failed 
to detect viral DNA in any of these tissues 64,94-96.  None of these studies determined the 
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HHV-8 serostatus of the individuals and thus these conflicting results may be due to the 
low HHV-8 seroprevalence (<10%) in the population 65.   
HHV-8, like other herpesviruses can establish both lytic and latent infections.  During a 
lytic infection, the majority of the viral genes are expressed and viral replication occurs 
(reviewed in 35.  Two examples of lytic genes are the viral homologue to IL-6 (vIL-6) and 
K8.1, a late glycoprotein 97,98.  During a latent infection a small subset of viral genes is 
expressed and viral replication does not occur.  An example of a latent viral gene is the 
latency associated nuclear antigen -1 (LANA-1)35.  Like most herpesviruses, the normal 
life cycle of HHV-8 most likely consists of a latent infection interspersed with occasional 
episodes of reactivation resulting in lytic infections. 
In this study, we performed immunohistochemistry on normal, non-cancerous prostate 
tissue of men from the MACS (Multicenter AIDS Cohort Study) group.  Serial sections 
were examined for expression of a viral protein expressed during latency, the latent 
nuclear antigen-1 (LANA-1) and two viral proteins expressed during replication of the 
virus (vIL-6 and K8.1).  Localized inflammation was determined by using a 
macrophage/monocyte marker, CD68, and a B-cell marker, CD20.  We also determined 
if cellular proliferation was evident as measured by expression of Ki67.   
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2.4 Methods 
 
2.4.1  Immunohistochemistry/ Immunofluorescence 
Paraffin sections were cut at 5µm and mounted on Surgipath microslides snowcoat X-
tra. The serial sections were deparaffinized in 3 xylene washes and rehydrated in a 
series of ethanol grades (100%, 95%, and 70%) to water.  Antigen retrieval was 
performed using Target retrieval buffer (Dako cytomation cat. # S1699) in a rice 
steamer for 40 (LANA-1) or 20 (vIL-6, K8.1, CD68, CD20, Ki67 and PSA) min.  Blocking 
of endogenous peroxidases was done in methanol and H2O2 for 20 min.  Non-specific 
proteins were blocked with either normal rabbit serum (LANA-1 and CD68) or normal 
goat serum (vIL-6, K8.1, CD20, Ki67, and PSA) for 30 min. at room temperature.  Anti-
ORF 73 (anti-LANA-1) rat monoclonal, anti-ORF K8.1 mouse monoclonal,  and anti-
HHV-8 vIL-6 polyclonal rabbit were used as primary antibodies at a concentration of 
1:500. (ABI Cat. # 13-210-100, 13-213-101,13-214-050, respectively).  Anti-CD20 a 
mouse monoclonal antibody, anti-CD68 a goat monoclonal, and anti-PSA mouse 
monoclonal (Abcam cat # ab9475-250, Santa Cruz Cat. # sc-7082, and Chemicon Cat. 
# MAB4082, respectively ) were used as primary antibodies at a concentration of 1:250.  
Anti-Ki67 (Abcam cat # ab6526), a mouse monoclonal antibody  was used at a 
concentration of 1:100.  Incubation of primary antibodies occurred overnight at 4°C in a 
humidified chamber.  Biotinylated rabbit anti-rat IgG, goat anti-mouse IgG, goat anti-
rabbit IgG, and rabbit anti-goat IgG, were used as secondary antibodies (Vector labs 
Cat. # BA-400, BA 9200, BA-1000, and BA-5000 respectively).  Incubation of the 
 
 
26
secondary antibodies occurred for 60 min. at room temperature in a humidified 
chamber.  Vector ABC Elite (Cat. # PK-7200) and Vector NovaRED substrate (Cat. # 
SK4800) were used to develop the staining for IHC.  Hematoxylin was used as the 
counter stain for immunohistochemistry.  The immunofluorescence procedure used 
rabbit anti-goat IgG FITC and goat anti-mouse IgG FITC as secondary antibodies 
(Sigma Cat. # F7367 and Roche Cat. # 0311769001).  The slide reader was blinded to 
the HHV-8 serostatus of each subject when viewing the different viral antibody stains. 
2.4.1 Prostate Tissues  
Prostate tissues taken during autopsy were analyzed by IHC from 18 men, 16 HHV-8 
seropositive and 2 HHV-8 seronegative subjects, from the Multicenter AIDS Cohort 
Study (MACS), a longitudinal study of HIV infection among men who have sex with men 
in the United States99.  HHV-8 serostatus was determined using an 
immunofluorescence assay as described previously 100.  All subjects were HIV positive 
men who have sex with men and who died with AIDS.  Hematoxylin and eosin (H&E) 
staining was performed on all samples to determine cancer status.  The type of HHV-8 
infection was discerned by the presence of LANA-1 for latent infections and the 
presence of K8.1  and vIL-6 for lytic infections.  Controls consisted of staining serial 
sections with normal rat, mouse, rabbit, or goat serum as the primary antibody.  A TPA-
induced BCBL-1/BJAB mixture along with a KS anal lesion were used as positive 
controls for the viral staining. BCBL-1 is a B cell line that is HHV-8 positive 101] while 
BJAB is a well studied, HHV-8 negative B cell line. 
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2.5 Results 
 2.5.1 Subject characteristics 
The MACS prostate samples represent men with non-cancerous prostate tissue, taken 
at autopsy, who are both seropositive (n=16) and seronegative (n=2) for HHV-8.  All 
subjects were HIV positive men who have sex with men and died with AIDS.  The 
prostate samples were stained with hematoxylin and eosin to determine cancer status 
and all were deemed cancer free by pathological examination. Table three lists the 
subject characteristics and selected protein expression.    The mean age at death was 
44.3 years.  Seven of the men had KS at death and four of these had documented 
visceral KS. The duration of KS from time of diagnosis to death of these seven men 
ranged from 10 mo. to 31 mo. with a mean duration of 18.1 mo.   
2.5.2 IHC/ IFA staining  
The IHC staining conditions for HHV-8 proteins were established using 2 different 
controls specimens.  One was a KS lesion and the other was a 2:1 mixture of TPA 
induced BCBL-1 cells and BJAB cells.  The KS lesion demonstrated numerous LANA-1 
positive cells (Figure 4A), fewer K8.1 positive cells, and a few vIL-6 positive cells (data 
not shown).  The BCBL-1/ BJAB cell mixture demonstrated strong staining for all three 
HHV-8 proteins (Figure 4 B-D).  Negative controls consisted of staining serial sections 
with normal rat, mouse, or rabbit serum as the primary antibody; there was no staining 
detected in any of the negative control serial sections (data not shown).   
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HHV-8 protein expression as detected by IHC in the individual prostates is listed in 
Table 1 and representative stained sections are shown in Figure 5.  For each sample, 
three serial sections were stained for each of the three viral proteins.  Among the HHV-8 
seronegative subjects, HHV-8 protein expression was not detected (Table 3).  Among 
the HHV-8 seropositive subjects, we detected viral protein expression in multiple 
regions of each section.  In some instances, the stained regions consisted of both lytic 
and latent protein expression, while other regions contained only lytic or only latent 
proteins.  Among the HHV-8 seropositive subjects, the majority of samples (68.9% or 
11/16) expressed at least one HHV-8 protein (summarized in Figure 6).   The 
combination of all three proteins (LANA-1, vIL-6, and K8.1), suggesting the presence of 
both lytic and latent viral infections within the same section was seen in 43.8% (7/16) of 
the samples.  vIL-6 expression was detected only in prostate tissues in which LANA-1 
and K8.1 expression was seen.   In a similar fashion, LANA-1 expression was detected 
only within sections in which K8.1 expression was also present; and this occurred in 
18.8% (3/16) patients.  Five of the 16 prostates from HHV-8 seropositive patients 
(31.3%) did not express any HHV-8 proteins (Figure 6).   
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Table 3. Subject Characteristics and Protein Expression Results 
            Protein Expression 
 
 Age 
@ 
death 
KS  
status 
Visceral 
KS 
Y or N 
Duration 
of KS 
HHV8 
serostatus 
LANA-
1 
 
vIL-6 
 
K8.1 
 
CD68 CD20 Ki67 
1 44 N - - - - - - Focal  None None 
2 57 N - - - - - - None None None 
3 41 N - - + + + + Focal None None 
4 47 N - - + + + + Diffuse None None 
5 40 Y N 16 mo. + + + + Diffuse None None 
6 49 N - - + + + + None None None 
7 46 Y N 14 mo. + + + + Diffuse None None 
8 30 N - - + + + + Focal None None 
9 39 N - - + + + + None None None 
10 43 N - - + + - + None None None 
11 41 Y Y 10 mo. + + - + None None None 
12 51 N - - + + - + None None None 
13 33 Y Y 18 mo. + - - + Focal None None 
14 45 N - - + - - - None None None 
15 51 Y Y 31 mo. + - - - Focal None None 
16 48 N - - + - - - None None None 
17 33 Y N 17 mo. + - - - None None None 
18 49 Y Y 21 mo. + - - - None None None 
 
To determine the amount of inflammation in each prostate, individual sections were 
stained with antibodies directed against CD20, a pan-B-cell marker, and CD68, a 
membrane-bound protein found primarily on macrophages.  CD20 was not detectable in 
any of the sections indicating a lack of B cell infiltrate (Table 3).  Three types of staining 
reactions however, were seen with the anti-CD68 antibody.  The lowest level of CD68 
staining had an occasional macrophage present in the tissue and was labeled no 
inflammation (Figure 7B).  There were two different CD68 staining patterns reflecting 
increased inflammation.  Sections that exhibited pronounced areas of staining 
consisting of several cells in each area were labeled as focal staining (Figure 7 D,E).  
Sections that exhibited many individual or small groups of macrophages located 
throughout the tissue were labeled diffuse (Figure 7 G,H).  The staining results are 
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listed in Table 3.  Among the seropositive samples, 20% (1/5) of the samples that did 
not express viral proteins exhibited inflammation compared to 54.5% (6/11) of the 
samples that expressed at least one viral protein.  Thus expression of at least one viral 
protein was associated with increased inflammation.   
Upon examination of the prostate sections, expression of viral proteins was not limited 
to exclusively latent or only lytic antigens.   Rather both classes of proteins were seen.   
The majority of sections expressed both LANA-1 and at least one lytic protein (Table 3).  
The expression of LANA-1 was separate and distinct from the lytic antigens.  
Interestingly, the three sections that demonstrated diffuse CD68 staining exhibited 
diffuse lytic antigen staining.  The lytic viral antigen positive cells were seen in clusters 
throughout the section in both the glandular epithelial and stromal compartments.   
Those sections that exhibited focal CD68 staining and were positive for lytic viral 
antigen, expressed the lytic viral antigen in scattered clusters throughout the tissue.  
The sections that did not exhibit much CD68 staining still expressed lytic viral antigen in 
smaller scattered clusters in both the glandular epithelial and the stromal compartments.  
LANA-1, the representative latent viral antigen, was seen predominately in the glandular 
epithelial region.  We observed that LANA-1 expression was rather consistent 
throughout the sections irrespective of the CD68 status.  Within each distinct viral 
positive area, there were anywhere from 3-54 positive cells.  Sections were measured 
and the average area of the section was determined to be 36.66 mm2.    
To determine if cell proliferation was present in the prostate samples, the sections were 
also stained with an antibody directed against Ki67, a cellular proliferation antigen.  
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None of the sections demonstrated the presence of Ki67 indicating a lack of cell 
proliferation in the prostate samples (Table 3). 
To determine if the cells expressing viral proteins were infiltrating macrophages or 
prostatic epithelia, separate sequential, serial sections were stained for CD68, viral 
antigen (LANA-1, vIL-6 or K8.1) and PSA.  Analyses of the stained sections revealed 
that LANA-1 staining was present only in prostatic cells and not in infiltrating 
macrophages (Figure 8), while vIL-6 and K8.1 were present in both types of cells.  
Figure six shows an example of serial sections stained with CD68, vIL-6, and PSA.  In 
this section vIL-6 expression is seen in both CD68-positive macrophages as well as 
PSA-positive prostatic epithelia.  In general, LANA-1 positive cells were found 
predominately in the prostatic glandular epithelium while lytic cycle proteins were found 
in both the epithelial and stromal compartments of the prostate.     
2.6 Discussion 
In the present study we addressed whether or not HHV-8 could be detected in normal 
(non-cancerous) prostate tissues of HIV-infected men using immunohistochemistry and 
immunofluorescence.  We analyzed prostates collected at autopsy from 18 men who 
were HIV positive and died with AIDS.  None of these men had prostate cancer as 
determined by histological analysis, two were HHV-8 seronegative as demonstrated by 
serology, and seven were positive for KS, four with visceral KS.  The results clearly 
demonstrate that HHV-8 infected cells are present in a majority of cancer-free prostates 
of HIV-infected,  HHV-8 seropositive men, with the detection of viral proteins not caused 
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by the presence of KS since a significant number of the samples that were positive for 
HHV-8 expression were from men with no evidence of KS.  In fact, there was no 
correlation between HHV-8 gene expression and the presence of KS.  
Viral gene expression was found in both the infiltrating monocyte/macrophages and in 
the prostatic glandular epithelium.  It is noteworthy that LANA-1 expression (indicating a 
latent viral infection) was found only in glandular epithelia and not in infiltrating 
macrophages while gene expression representing a viral lytic cycle (vIL-6 and K8.1) 
were expressed in both cell types.  This suggests that HHV-8 establishes a latent 
infection in prostatic cells and that infiltrating macrophages do not enter the prostate 
latently infected.  The expression of viral lytic genes in the macrophages may indicate 
that the macrophages have either become infected with HHV-8 in the prostate or have 
engulfed cells expressing viral proteins.  Previous reports have documented the ability 
of HHV-8 to infect macrophages 102-104.   
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A. Staining for LANA-1 40x, inlay 100x  B. Staining for LANA-1 40x, inlay 100x 
 
C. Staining for K8.1 40x, inlay 100x  D. Staining for vIL-6 40x, inlay 100x 
 
Figure 4: HHV-8 Protein Expression in a KS section and B-cell 
A. KS lesion stained for LANA-1. B,C, and D show a 2:1  BCBL-1/BJAB  mixture. B is 
stained for LANA-1, C is stained for K8.1, and D is stained for vIL-6.  Pictures were 
taken at 40x with the insert at 100x. 
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A. Negative control 40x, 100x inlay           B. Staining for LANA-1 40x, 100x inlay 
          
C. Negative control 40x, 100x inlay             D. Staining for K8.1 40x, 100x inlay 
     
E. Negative control 40x, 100x inlay             F. Staining for vIL-6 40x, 100x inlay  
                                                                       
Figure 5: HHV-8 Protein Expression in the Prostatic Tissues of Seropositive Men.  
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Sections were stained with antibodies directed against LANA-1 (A), K8.1 (C), or vIL-6 
(E).  Serial sections were stained with normal rat (B), mouse (D), or rabbit (F) as 
negative control. 
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Figure 6: HHV-8 Protein Expression Based on KS Status in Prostates of Seropositive Men 
HHV-8 Protein Expression Based on KS status in Prostates of Seropostive Men.  The 
graph shows the percentage of subjects that expressed HHV-8 proteins (LANA-1, K8.1, 
& vIL-6) together or those that expressed at least one of the HHV-8 proteins.  Also 
shown, are those subjects that expressed no HHV-8 proteins.  All subjects represented 
above were HHV-8 seropositive. 
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Figure 7: CD68 Expression in the Prostates of Three Representative Subjects.  
All negative control slides are stained with goat serum.  A and B are serial sections, A 
shows the negative control slide at 40x and B shows a representative no (N) 
inflammation staining at 40x with the insert at 100x. C,D,and E are serial sections, C 
shows the negative control slide at 10x, D shows a representative focal (F) inflammation 
staining at 10x, and E shows the same slide in D at 40x with an insert at 100x.  F,G,and 
H are serial sections, F shows the negative control slide at 10x, G shows a 
representative diffuse (D) inflammation staining at 10x, and H shows the same slide in 
G at 40x with an insert at 100x. 
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A.  Staining for Dapi 40x         B. Staining for vIL-6 40x 
       
 
 
 
 
 
C. Staining for CD68 40x          D. Staining for PSA 40x  
 
 
 
 
 
Figure 8: Serial Sections Stained with CD68,vIL-6, and PSA. 
A. dapi staining. B. vIL-6 staining.  C. CD68 staining.  D. staining for PSA.  The red 
arrows represent vIL-6, CD68 positive cells; the white arrow represents a vIL-6, PSA 
positive cell.  The yellow arrow represent a positive vIL-6 cell that is negative for both 
CD68 and PSA.  All pictures were taken at 40x.          
 
 
 
We also detected cells present in the prostate that were positive for vIL-6 and negative 
for both CD68 and PSA.   The CD20 staining showed that infiltrating B-cells were not 
present in the infected prostate.  It is possible that these infected cells are prostatic 
stromal cells.  Additional staining will be required to identify the cells.  Nonetheless, our 
results demonstrate that HHV-8 can infect prostate cells and establish a latent infection. 
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Our results support the results of Diamond et al 93 who reported that HHV-8 could 
establish infections in prostate tissue of HIV-infected men.  Our data extends their 
report in that we have detected the expression of multiple viral proteins by IHC while the 
previous study used in situ hybridization to detect viral mRNA, a method that has been 
criticized for false positive results due to edge artifact.  In addition we have analyzed a 
total of 18 HHV-8 seropositive and seronegative men both with and without KS, while 
the Diamond study analyzed eight KS patients.    
We have shown that prostates of HIV-infected men known to express HHV-8 proteins 
have increased levels of inflammation as measured by the presence of infiltrating 
macrophages.  This increased inflammation is not due to an increase in the presence of 
circulating blood since there was no substantial B cell infiltrate (as measured by 
antibodies to CD20).  This suggests the establishment of a chronic inflammation in the 
prostates of HHV-8 seropositive, HIV-infected men.  Interestingly, inflammation and 
sexually transmitted agents have been suggested as co-factors in the development of 
prostate cancer.  In support of this, we have previously reported an increased 
seroprevalence of HHV-8 among men with prostate cancer in the Caribbean island of 
Tobago 7.  The potential link between HHV-8 infection, inflammation, and prostate 
cancer deserves further study. 
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3.1 Preface 
 
The majority of the data contained in this dissertation involves immunohistochemical 
analyses.  In order to quantify immunohistochemical data, laboratories have one of two 
options:  they can manually count the cells or they can use a computer based method.  
Manual counting is laborious and time consuming and introduces the element of human 
error.  Computer based methods are the better option, but most computer image 
analysis software is expensive and beyond the budgetary reach of most small to 
medium laboratories.  We have the Alpha- Diga Doc RT ™ system in the laboratory, 
making it readily available to us.   To solve the problem of expensive image analysis, we 
developed this study to validate the use of the Alpha-Diga Doc RT™ system for the 
immunohistochemical image analysis. 
This study is In Press in Applied Immuno-histochemistry and Molecular Morphology.  I 
was first author on this paper.  I did all of the staining of the slides and served as reader 
1, along with developing the technique of using the computer program for cell counting. 
3.2 Abstract 
The aim of the present study was to determine if the Alpha DigiDoc RT™ system would 
be an effective method of quantifying immunohistochemical (IHC) staining as compared 
to a manual counting method, which is considered the gold standard.  Two readers 
were used to count 31 samples by both methods.  The results obtained using the Bland-
Altman for concordance deemed no statistical difference between the two methods.  
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Thus, the Alpha DigiDoc RT™ system is an effective, low cost method to quantify IHC 
data. 
3.3 Introduction 
 
A quantative evaluation of immunohistochemical (IHC) staining is limited to the 
determination of the percentage of positively stained cells in a given area or within a 
given number of cells 105,106.   Levels of staining based on intensity of stain cannot be 
determined due to the lack of uniform staining.  Currently, two options are available to 
quantify IHC staining; counting the positive cells manually, which is considered to be the 
gold standard, or using a computer-based counting program 107.  Manual counting is 
laborious, time consuming, and somewhat prone to human error.   However, most 
computer-based methods of counting, which require less time and reduce the possibility 
of human error, are expensive and beyond the budget of most small to medium 
laboratories 108.   For these reasons, the identification of a low cost computer-based 
counting program which is effective, determined by being fast, accurate, and reliable, 
would be of great interest to many laboratories. 
The goal of this study was to determine if the Alpha DigiDoc RT™ system is 
comparable to manual counting in determining the percentage of IHC stained cells in a 
given area.  We chose the Alpha DigiDoc RT™ system for its affordability and ease of 
use. 
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3.4 Materials and Methods 
 
3.4.1 Immunohistochemistry 
Paraffin sections from 31 cases of prostate cancer were analyzed as described in 
chapter 2 section 2.4.1.  The differences in the procedure are noted as follows.   
Monoclonal anti CD3 antibody was used as primary antibody at a concentration of 
1:500. (Santa Cruz Cat. # sc-1239).   Biotinylated goat anti mouse IgG was used as a 
secondary antibody (Vector labs Cat. # BA 9200).  Optimal concentrations for the 
primary and secondary antibodies were determined using paraffin sections from a 
leukocyte block.  Once the optimal antibody concentrations were determined, the 
procedure was performed on the human tissue samples.   
3.4.2  Image Acquisition  
Images were obtained using a Micromaster microscope from Fisher Scientific (cat. # 12-
560-48) at one magnification (200x).  The image capturing software was Micron 1 
(Westover Scientific cat # ZP-MC-0036[A]).  This gave an area of 640 x 480 pixels and 
each pixel occupied 24 bits (8 bits for red, green, and blue, respectively) (Figure 9A).   
One picture from each of 31 total slides taken at 200x was used for the analysis.   
 3.4.3 Manual counting method   
Images were imported into Microsoft Paint and a grid of 0.062 in2 was applied (Figure 
9B).   Two separate readers were employed to determine the percentage of stained 
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cells by counting both the number of stained and unstained cells in the grid from each of 
the 31 pictures (positive cells stained red in color).   
3.4.4 Alpha DigiDoc RT™ Counting Method 
Images were imported into the Alpha DigiDoc RT™ system (AlphaEase FC software 
4.1.0) and equalized using the software.  This allowed the colors to sharpen and 
become more distinct.  The images, as described above, were converted to 8-bit 
grayscale.  The grid was selected and threshold was determined by the reader.  The 
threshold function allows the operator to determine the level of staining to be labeled as 
positive.  Using VectorRED, positively stained cells stain as reddish-brown, while 
negtively stained cells are clear with a light blue nucleus due to hematoxylin counter 
stain.  When this color image is converted to grayscale, the reddish-brown (positive) 
cells appear darker when compared to the negative cells.  By adjusting the threshold 
the operator can insure that the positive cells are selected for counting.  The software’s 
auto count function then determines the number of positive cells within the grid.  If the 
reader disagrees with the computer’s determination regarding the staining of a particular 
cell, then that cell could be removed or added from the count by use of the manual 
tools.  This function permits the removal of erroneous material, such as cellular debris 
and other staining artifacts that may be present in the section.  Next, the total cell count 
was determined by changing the threshold such that all of the cells in the area are 
selected as positively stained.  From these results the percent positive cells was 
determined.  This progression can be seen in Figure 10.   
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3.4.5 Statistical Analysis  
The degree of concordance between the 2 methods was determined by Bland-Altman 
plots109,110 109.  Each comparison was subjected to a power analysis, assuming equal 
variances in readers, to determine if there was significant power to detect the observed 
bias.   
3.5 Results and Discussion 
3.5.1  Adaptation of the Digi-Doc RT™ system for analysis of IHC stained sections 
To adapt the Alpha DigiDoc RT™ system for IHC stained sections, we analyzed 31 
prostatic biopsy sections stained with a monoclonal anti-CD3 antibody which detects the 
presence of T lymphocytes.  Our staining protocol results in the CD3 positive cells 
staining reddish-brown.  Hematoxylin was used as a counterstain so that the nuclei of 
all cells (both positive and negative stained cells) appear blue.  Stained sections were 
photographed as shown in Figure 9 and a 0.062 in2 grid was applied to a representative 
area (Figure 9B).   This image was then imported into the Alpha DigiDoc RT™ program.  
Figure 10 shows the progression from the original photograph through the selection of 
positive cells using the Alpha DigiDoc RT™ program.  The original image was equalized 
by the software to allow for better color distinction (Figure 10B).  The image was 
converted to grayscale, the threshold was applied to the grid of interest, and the percent 
positive cells were determined (Figure 10C-G).  Once a percentage was calculated, the 
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results were plotted and compared by Bland-Altman.  This process was performed on 
31 samples. 
A.         B. 
               
Figure 9: Example of Picture and Grid| 
A.)Picture of sample taken with the Micron 1 software on the Micromaster microscope 
B.) Picture with the 0.062 inch2 square added.  The square represents the area to be 
analyze. 
3.5.2 Comparison of Readers Using Manual Counting and Alpha DigiDoc RT™ 
program 
We first determined if there was any significant difference between the two readers 
using either manual counting or the computer method in determining the percentage of 
positive cells.  As shown in Figure 11A, the comparison between manual counting of 31 
separate sections by the two readers using the Bland-Altman plot indicated that there 
was not significant error.  The average percent difference between the two readers 
using manual counting was -0.13.  Further, there was also no significant error found in 
comparisons between the Alpha DigiDoc RT™ program of the different sections by the 
two readers.   The average percent difference between the two readers using the Alpha 
DigiDoc RT™ system was 7.04 (Figure 11B).   
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A. Picture from Micron 1    B. Picture Equalized         C. Gray Conversion 
      
D. Total Cells (Threshold)     E. Positive Cells (Threshold)    F. Erased Cells 
      
G. Final Count of Positive Cells 
 
  
 
 
 
Figure 10: Alpha Digidoc™ Counting Method 
A.) Picture of sample taken from the Micromaster microscope using Micron 1 software 
B.) Picture equalized in Alpha DigiDoc RT™ C.) Picture converted to grayscale in Alpha 
DigiDoc RT™ D.) Total cells as determined by Alpha DigiDoc RT™ E.) Positive Cells as 
determined by Alpha DigiDoc RT™ F.) Erased cells as determined by reader G.) Final 
count of positive cells 
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3.5.3 Comparison of Manual Counting and Alpha DigiDoc RT™ program 
The comparison of manual and computer-based results are also presented with Bland-
Altman plots.  As shown in Figure 11C, the two methods were comparable with each 
reader.  The average percent difference between the two methods was 5.26 (Reader 1) 
and 12.43 (Reader 2).   
Using two separate readers to analyze 31 separate IHC stained sections, it was 
determined that no significant bias was detected between manual counting and Alpha 
DigiDoc RT™ program.  This program was found to be fast, reliable, and cost-effective, 
enabling small to medium size labs an affordable method for computer based 
quantification of IHC staining.  It is noteworthy that of the two readers used in this study, 
one had over three years experience reading IHC slides, while the other had less than 
one month.  This demonstrates that the Alpha DigiDoc RT™ program can be used by 
both experienced and inexperienced individuals for semi-quantitative analysis of IHC 
stained slides.    
The Alpha DigiDoc RT™ was designed for colony counting, but the novel method 
(described in the present study) of using it for counting cells stained by 
immunohistochemistry allows labs with restricted budgets to semi-quantitatively analyze 
their stained slides.   In addition, the Alpha DigiDoc RT™ can be used with any image 
capture software.   The authors used the Micron 1 (Westover Scientific cat # ZP-MC-
0036[A]) image capturing software, which is included when a Micromaster microscope 
is purchased for $2,243 from ThermoFisher.  The cost of the Alpha DigiDoc RT™ is 
$826; thus, this semi-quantative method of cell counting can be purchased for 
 
 
49
approximately $3,000.  The cost of a more conventional system using software 
specifically designed for analyzing stained tissue sections (such as Metamorph, 
Molecular Devices) is approximately $14,000, almost 5 times the cost of using the Alpha 
DigiDoc RT™ system.  The Alpha DigiDoc RT™ system can be useful for the 
quantification of many different cell types such as, cytokine producing cells, individual 
populations as identified by expression of various cellular markers, proliferating cells, 
and apoptotic cells.  Therefore, this system could be a very powerful tool, due to its wide 
applicability and low-cost, for multiple applications. 
3.6 Acknowledgements 
 
The funding for this study was provided by the University of Pittsburgh Cancer Institute.   
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(Figure 11 Continued Below) 
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Figure 11: Bland-Altman plots of Concordance 
(A) Manual count, reader 1 vs. reader 2 (B) Alpha DigiDoc RT™ use, reader 1 vs. 
reader 2 (C) Reader 1, manual vs. Alpha DigiDoc RT™ program (D) Reader 2, manual 
vs. Alpha DigiDoc RT™ program. 
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4.0 Chapter Four:  Detection of HHV-8 in Cancerous Prostates from Tobago. 
4.1 Introduction 
 
We have previously shown that HHV-8 is present in normal, non-cancerous prostates 
and expresses both lytic and latent proteins (Chapter 2, 88).   We have also shown that 
the presence of HHV-8 protein expression in the prostate results in an increased 
inflammation as determined by increased immune infiltrate (Chapter 2;88).  The study 
described in Chapter 2 was conducted on non-cancerous prostates from men that died 
with AIDS.  If HHV-8 is an infectious agent cofactor for prostate cancer, then we should 
also be able to find it in cancerous prostates of seropositive men.  In addition, we need 
to determine if the virus is present in cancerous cells or surrounding normal cells. 
In this Chapter, we will describe analyses of prostate samples of men from the 
Caribbean island of Tobago.  The cohort is divided into two study groups, biopsy 
material from 19 men and prostatectomy material from 20 men.    The biopsy group 
consists of 19 men, 12 seropositive for HHV-8 and 7 seronegative for HHV-8.  The 
prostatectomy group consists of 19 men, 11 seropositive and 9 seronegative for HHV-8; 
the prostatectomy group has tissue blocks representing areas of the prostate with 
cancer and areas that are cancer-free (as determined histologically by a pathologist). 
In addition, previous work from our laboratory has demonstrated an interaction between 
a R148G polymorphism in the gp130 signaling receptor of human IL-6 and HHV-8 
seropositivity that results in an increased risk for prostate cancer in Tobago (see section 
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1.7 table 2).  As a result, we have selected prostatectomy cases based on both HHV-8 
seropositivity and gp130 genotype (Figure 12). 
     
Figure 12: Breakdown of Tobago Prostatectomy Subjects by HHV-8 seropositivity and gp130 allele 
status. 
 
In this study, we performed immunohistochemistry on cancerous prostates from 39 
men, 20 who received prostatectomies and 19 men who received biopsies from 
Tobago.  Serial sections were examined for expression of the latent HHV-8 viral protein, 
LANA-1, the lytic viral proteins, K8.1 and vIL-6 (for biopsy only).  Localized inflammation 
was determined by using a macrophage/monocyte marker, CD68, and a B-cell marker, 
CD20 (only on the prostatectomy subgroup, see table 4).     
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4.2 Methods 
4.2.1 Immunohistochemistry 
See section 2.4.1 of Chapter 2 
The type of HHV-8 infection was discerned by the presence of LANA-1 for a latent 
infection and the presence of vIL-6 and/or K8.1 for lytic infection.  Controls consisted of 
staining serial sections with normal rat, mouse, or goat serum depending on the species 
of the primary antibody.  A TPA-induced BCBL-1/BJAB mixture was used as positive 
control for the viral staining.  BCBL-1 is a B cell line that is HHV-8 positive 101  where 
TPA induced cells act as a lytic control and uninduced cells act as a latent control.  The 
BJAB line is a well studied, HHV-8 negative B cell line. 
4.2.2 Subjects 
A full description of the Tobago Prostate Survey is given in Bunker et. al 6.  Briefly, the 
study is ongoing in the Caribbean island of Tobago.  The protocol was approved by both 
the Institutional Review Boards of the University of Pittsburgh and the Division of Health 
and Social Services, Tobago House of Assembly.  Participants in the study are recruited 
mostly by public service announcement and by word of mouth.  Thus far, 60% of the 
male residents between the ages of 40-79 are enrolled.  Each participant receives a 
PSA screening and a digital rectal exam (DRE).   Those patients having an elevated 
PSA, 4.0 ng/ml or more, or an abnormal DRE are referred to Tobago Regional Hospital 
for sextant biopsy.  The biopsy prostate tissues were taken during this routine surgery 
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while the prostatectomy samples were taken during a subsequent surgery.  Hematoxylin 
and eosin staining was performed on all samples to determine cancer status. 
 4.2.3 HHV-8 Serology 
HHV-8 serostatus was determined using an immunofluorrescence assay as described 
previously 100.    
 4.2.4 Percentage of positive cells 
See sections 3.4.2 and 3.4.4.   
4.2.5 Statistics 
 
The SPSS statistical package was used for statistical analysis.  All populations were 
assumed to be non-parametric.  We used the Wilcoxin signed ranks test and the Mann-
Whitney test to determine statistical significance. 
4.2.6 gp130 Genotyping 
Determination of gp130 genotype was performed by Dr. Robert Ferrell’s laboratory in 
the Department of Human Genetics, Graduate School of Public Health, University of 
Pittsburgh.  The primers used were, forward (5’ccagcaaaaatgactaac 3’), and reverse 
(gttgcattgtgaacgagg).  The annealing temperature was 54⁰C with a Magnesium Chloride 
salt concentration of 2.0mM.  The detection sequence primer was (5’ 
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caagtgtgtttcccttccac 3’).  All polymerase chain reactions (PCR) were done at 35 cycles 
of 95⁰C for 30 sec, annealing temperature for 30 sec, followed by 30 sec of 72⁰C.   Ten 
microliters of the PCR product was cut with SAP/EXO to remove excess primers and 
dinucleotide triphosphates, dNTPs.  Following digestion of the PCR product, a one base 
pair extension at position 148 was done with fluorescently labeled dNTPs for detection. 
4.3 Results 
4.3.1 Characterization of the Tobago Biopsy Subgroup 
The Tobago biopsy subgroup represents men with prostate cancer where the tissue 
was taken at biopsy.  All subjects were deemed cancerous by pathological examination.  
Table 4 lists the subject characteristics and protein expression for the biopsy study 
group.  Figure 13 shows the percentage of seropositive men who demonstrated antigen 
expression of at least on protein, LANA-1, vIL-6, or K8.1. 
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Table 4: Subject Characteristics and Protein Expression Results of Cancerous Biopsies of 
Prostates from Tobago. 
 
Number  Gleason 
Score 
Serostatus  LANA  % 
LANA 
vIL‐
6 
%  
vIL‐6 
K8.1  % 
K8.1 
CD68  Ki67 
1  6  ‐  ‐  0  ‐  0  ‐  0  +  + 
2  7  ‐  ‐  0  ‐  0  ‐  0  +  + 
3  6  ‐  ‐  0  ‐  0  ‐  0  +  + 
4  8  ‐  ‐  0  ‐  0  ‐  0  +  + 
5  7  ‐  ‐  0  ‐  0  ‐  0  +  + 
6  7  ‐  ‐  0  ‐  0  ‐  0  +  + 
7  9  ‐  ‐  0  ‐  0  ‐  0  +  + 
8  8  +  ‐  0  ‐  0  ‐  0  +  + 
9  8  +  ‐  0  ‐  0  ‐  0  +  + 
10  8  +  ‐  0  ‐  0  ‐  0  +  + 
11  6  +  ‐  0  ‐  0  +  0.01  +  + 
12  6  +  ‐  0  ‐  0  +  10.43  +  + 
13  7  +  ‐  0  +  9.01  ‐  0  +  + 
14  8  +  ‐  0  +  8.46  ‐  0  +  + 
15  6  +  +  5.56  ‐  0  ‐  0  +  + 
16  7  +  +  12.12  ‐  0  ‐  0  +  + 
17  6  +  +  16.85  ‐  0  ‐  0  +  + 
18  6  +  +  1.75  +  7.25  ‐  0  +  + 
19  6  +  +  7.25  +  4.44  ‐  0  +  + 
 
Table 4 shows the subject characteristics of the Biopsy subgroup.  %protein means the 
number of positively stained cells in the specified grid. (see chapter 3). 
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 Figure 13:  HHV8 Protein Expression in the Cancerous Biopsies.   
The graph shows that 75% of the seropositive subjects expressed at least one protein 
(LANA-1, K8.1, or vIL-6) and that 25% of the seropositive subjects expressed no viral 
proteins. 
 
4.3.2 Viral Protein Expression by IHC Staining- Tobago Biopsy Subgroup 
The conditions for IHC established in section 2.5.2 are the same used in this study.  
Briefly, we used two different controls to optimize the staining, a KS lesion and a 2:1 
BCBL-1: BJAB mix.  Figure 14 shows staining for all HHV-8 proteins, LANA-1, vIL-6, 
and K8.1 in a representative prostate biopsy samples.  Negative controls consisted of 
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staining serial sections with normal rat or mouse serum as the primary antibody.  The 
arrows indicate areas of cancer. 
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 E F
Figure 14: HHV-8 Proteins in the Prostate, but not in the Cancer. Tobago Biopsy Subgroup. 
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A. Shows staining for K8.1 at 400x, insert at 1000x. B. Shows negative control staining 
for normal mouse serum at 400x. C. Shows staining for vIL-6 at 400x, insert at 1000x.  
D. shows staining for normal rabbit serum at 400x. E. Shows staining for LANA-1 400x, 
insert 1000x. F. Shows staining for normal rat serum 400x.  The arrows indicate areas 
with cancer. 
 
HHV-8 protein expression as detected by IHC in the biopsy prostates is shown in Table 
4.  Each subject had serial sections from the paraffin block stained for LANA-1, vIL-6, 
and K8.1.  Among the HHV-8 seropositive subjects, viral protein expression was 
detected in multiple regions of each section, but not in the cancer.  Some of the subjects 
show both lytic and latent expression in the stained regions, while other regions 
contained only latent or lytic.  HHV-8 protein expression was not seen in any of the 
HHV-8 seronegative subjects.  All subjects stained positive for Ki67, a marker of cellular 
proliferation which is often used to demonstrate the presence of cancer. 
Among the seropostive subjects, HHV-8 protein expression of at least one protein was 
seen in 75% (9/12) of the biopsies (summarized in figure 13).  LANA-1 was expressed 
in the majority of stained sections, 5/9 or 55.6%.  Three of the twelve HHV-8 
seropositive men did not express any HHV-8 proteins (Table 4).   
In order to determine the amount of inflammation in each prostate, individual sections 
were stained with antibodies directed against CD68, a macrophage marker.  
Representative samples can be seen in Figure 15.    We used a semi-quantative image 
approach developed in our laboratory and described in sections 3.4.2 and 3.4.4 of this 
dissertation to determine the percentage of macrophages present in a defined area.  
This analysis produces a total number of positive cells that is adjusted for total cell 
number.  These results are shown in Table 4.    
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 Figure 15:  CD68 Staining in the Tobago Biopsy 
A. Shows a representative prostate biopsy sample stained with CD68.  B. Shows the 
negative control serial section prostate biopsy stained with normal goat serum. 
 
There was no difference seen in the percentage of CD68-positive cells between the 
seronegative and seropositive subjects (Tables 5).   
 
Table 5. Differences in CD68 expression in Seropositive and Seronegative Subjects 
 %CD68 
Mean  of % positive 
CD68 staining 
+/- SD 
p* 
Seronegative 12.37 +/- 5.71 0.432 
Seropositive 12.4 +/- 12.61 
*Mann-Whitney U 
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 4.3.3 Characterization of the Tobago Prostatectomy Subgroup 
The Tobago Prostatectomy Subgroup represents men with prostate cancer who had 
their prostates removed with surgery.  The group is comprised of 20 men, all deemed 
cancerous by pathological examination.  The subjects were selected based on their 
HHV-8 serostatus and gp130 geneotype (Figure 12.)    
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Table 6: Subject Characteristics and Protein Expression-Tobago Prostatectomy 
Subject 
Cancer 
(C)/Non-
Cancer(NC) 
HHV-8 
Serostatus LANA 
% 
LANA K8.1 
% 
K8.1 CD68 
% 
CD68 CD20 
% 
CD20 
1 C + + 35.03 + 0.25 + 0.22 + 60.56 
1 NC + + 0.52 + 3.76 + 2.35 + 19.64 
2 C + + 0.56 + 0.26 + 9.44 + 40.16 
2 NC + + 1.35 + 1.01 + 5.91 + 5.36 
3 C + + 6.04 + 4.08 + 3.93 + 76.34 
3 NC + + 1.22 + 15.27 + 0.27 + 83.59 
4 C + + 31.67 + 2.44 + 2.5 + 33.85 
4 NC + + 11.46 + 6.69 + 37.69 + 60.55 
5 C + + 0.93 + 2.93 + 2.75 + 70.62 
5 NC + + 1.52 + 2.47 + 0 + 0.22 
6 C + + 17.87 + 7.63 + 70.61 + 2.24 
6 NC + + 2.4 + 6.15 + 0.695 + 3.15 
7 C + - 0 + 1.35 - 0 + 39.57 
7 NC + - 0 + 16.32 - 0 + 79.1 
8 C + - 0 + 0.87 + 0 + 87.54 
8 NC + - 0 + 0.67 + 0 + 53.12 
9 C + + 0.35 + 56.77 + 16.95 + 60.03 
9 NC + - 0 - 0 + 0 + 79.75 
10 C + - 0 - 0 + 26.56 + 77.12 
10 NC + - 0 + 2.44 + 3.48 + 26.56 
11 C + - 0 + 3.41 + 5.21 - 0 
11 NC + - 0 + 2.23 + 0 + 43.44 
12 C - + 3.13 + 13.03 + 0 + 31.09 
12 NC - - 0 - 0 + 0 + 39.83 
13 C - - 0 + 11.02 - 0 + 11.44 
13 NC - + 0.5 + 4.16 + 16.67 + 63.03 
14 C - - 0 - 0 + 4.32 + 60.58 
14 NC - + 3.66 - 0 + 11.93 + 73.97 
15 C - + 17.08 + 45.78 + 0.11 + 58.09 
15 NC - + 5.84 + 0.34 + 0.28 + 22.97 
16 C - + 5.59 + 0.33 + 1.03 + 44.26 
16 NC - + 11.09 + 0.99 + 0.51 + 58.45 
17 C - + 0.81 + 44.85 - 0 + 51.83 
17 NC - + 1.41 - 0 - 0 + 57.57 
18 C - - 0 - 0 - 0 + 27.19 
18 NC - - 0 - 0 - 0 + 11.5 
19 C - - 0 - 0 - 0 + 28.83 
19 NC - - 0 - 0 - 0 - 0 
20 C - - 0 - 0 - 0 + 45.29 
20 NC - - 0 - 0 - 0 + 45.85 
The table shows that for each subject I had a slide of an area with cancer (C) and a 
slide of an area without cancer (NC).  The proteins stained for were, LANA-1, K8.1, 
CD68, and CD20.  The percentages equal the percent of protein positive cells as 
determined by the threshold analysis described in chapter three. 
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Figure 16: HHV-8 Protein Expression in Prostatectomy Subgroup from Tobago. 
The graph shows the percent of subjects with and without cancer that stained positive 
for LANA-1 and K8.1 
 
4.3.4 IHC Staining- Tobago Prostatectomy Subgroup 
For each subject, there were paraffin blocks available representing areas with cancer 
and areas without cancer.  Sections from each block were stained for the viral proteins 
K8.1 and LANA-1.  Viral IL-6 staining was not done because in the previous MACS 
cohort it was not seen in many subjects and deemed unnecessary.    Negative controls 
were serial sections stained with normal mouse or normal rat as the primary antibody.  
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HHV-8 protein expression is listed in Table 6 and a representative stain is seen in 
Figure 17.  Each subject had serial sections stained for LANA-1 and K8.1.  Among the 
HHV-8 seropositive subjects, viral protein expression was detected in multiple regions 
of each section, but not in the cancerous cells.  Some of the subjects show both lytic 
and latent expression in the stained regions, while other regions contained only latent or 
lytic protein expression.  Frequently, if LANA-1 was present then K8.1  was also present 
(12/13) subjects.  Three of the nine seronegative subjects did not express viral proteins 
(see Table 6).   
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 Figure 17: HHV-8 Protein Expression in the Prostates of Seropositive men from Tobago 
Prostatectomy group. 
A. Shows staining for LANA-1 at 400x, inset at 1000x. B. Shows serial section staining 
for normal rat serum at 400x.  C. Shows staining for K8.1 at 400x, inset at 1000x. D. 
shows serial section staining for normal mouse serum at 400x. 
 
This subgroup contained tissue blocks representing areas with cancer (C) and areas 
without cancer (NC) from the same subject.  We asked whether there were differences 
seen in viral antigen expression, as measured by LANA-1 and K8.1 staining, within the 
same patient.  Table 7 shows that there was significant difference seen between areas 
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with cancer and areas without cancer based on viral antigen expression.  The areas 
with cancer exhibited a higher level of both K8.1 and LANA-1 staining. 
Table 7: HHV-8 Protein Expression is Higher in Cancerous Sections 
 LANA-1 K8.1 
Mean of % LANA-1 
positive cells 
+/- SD 
p* Mean of % K8.1 
positive cells 
 +/- SD 
p* 
Non-Cancer 2.91 +/- 4.49 0.001 3.68 +/- 5.02 0.000 
Cancer 6.75 +/- 11.13 11.42 +/- 18.55 
*Wilcoxon Signed Ranks Test 
This subgroup of the Tobago cohort was genotyped for the gp130 R148G allele that has 
been previously associated with a high risk for prostate cancer when combined with 
HHV-8 seropositivity.  We asked whether differences were seen in LANA-1 and K8.1 
expression based on gp130 status in the non-cancer sections.  Table 8 shows the 
results of the Mann-Whitney test.  No difference in viral protein expression was seen 
based on gp130 allele status in the non-cancerous areas. 
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Table 8: No Difference seen in HHV-8 Protein Expression Based on gp130 Allele Status in Non-
cancerous areas. 
 LANA K8.1 
Mean  of % LANA-
1 positive cells 
+/- SD 
p* Mean of % K8.1 
positive cells 
 +/- SD 
p* 
Non-Cancer 
High Risk 
3.55 +/-  3.98  
 
0.174 
3.47 +/-  4.68  
 
0.887 
Non-Cancer 
Low Risk 
2.40 +/-  5.01 3.97 +/-  5.85 
*Mann-Whitney Test 
 
In order to determine the amount of inflammation in each prostate, individual sections 
were stained with antibodies directed against CD68, a macrophage marker and CD20 a 
B-cell marker.  Representative staining can be seen in Figure 17.    To determine the 
total number of positive cells we used a semi-quantative image analysis developed in 
our laboratory and described in sections 3.4.2 and 3.4.4 of this dissertation.  That 
analysis produced a total number of positive cells that was adjusted for total cell 
number.  Those values can be seen in Table 6. 
We asked whether within the same subject there were differences seen in inflammation 
based on CD68 and CD20 expression.  Table 6 shows that differences were seen in 
inflammation; the areas with cancer exhibited an increased inflammation over the areas 
without cancer. 
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Table 9: Differences were seen in Inflammation between areas with and without Cancer within the 
same subject 
 CD20 CD68 
Mean of % CD20 
positive cells 
 +/- SD 
p* Mean of % CD68 
positive cells 
 +/- SD 
p* 
Non-Cancer 41.38 +/- 28.45  
0.000 
4.00 +/- 9.10  
0.009 
Cancer 45.33 +/- 24.43 7.19 +/- 16.40 
* Wilcoxin Signed Ranks Test 
We next asked if differences were seen in inflammation based on gp130 allele status.  
Table 10 shows the results of the non-cancerous sections.  Differences were seen in 
inflammation based on gp130 allele status; the gp130 high risk group exhibited an 
increase inflammation over the gp130 low risk group based on CD68 staining.  No 
difference was seen in the cancerous sections (data not shown). 
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Table 10: Differences in Inflammation Based on gp130 Allele Status in Non-Cancerous Sections 
  
CD20 
 
CD68 
 
Mean of % CD20 
positive cells 
 +/- SD 
 
p* 
 
Mean of % CD68 
positive cells 
 +/- SD 
 
p* 
Non-Cancer 
High Risk 
 
42.76 +/- 29.36 
 
 
 
0.739 
 
7.5610 +/- 12.06 
 
 
 
0.023 Non-Cancer 
Low Risk 
 
45.33 +/- 24.43 
 
.4395 +/- 1.09 
*Mann-Whitney Test 
4.3.5 Summary of Tobago Prostatectomy Subgroup 
We asked whether differences were seen in inflammation, as measured by CD68 and 
CD20 expression, or viral antigen expression, as measured by LANA-1 or K8.1 
expression, between areas with cancer and areas without cancer in the same patient.  
Table 11 shows the summary of the data for the Tobago Prostatectomy Subgroup. 
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Table 11: Summary of the Tobago Prostatectomy Subgroup 
* Wilcoxin Signed Ranks Test 
 LANA-1 K8.1 CD20 CD68 
Mean of 
% 
positive 
LANA-1 
cells 
 +/- SD 
p* Mean  
of % 
positive 
K8.1 
cells 
+/- SD 
p* Mean of 
% CD20 
positive 
cells 
 +/- SD 
p* Mean of 
% CD68 
positive 
cells  
+/- SD 
p* 
NC 2.91 +/- 
4.49 
 
 
0.001 
3.68 +/- 
5.02 
 
 
0.000 
41.38 
+/- 
28.45 
 
 
0.000 
4.00 +/- 
9.10 
 
 
0.009 
C 6.75 +/- 
11.13 
11.42 
+/- 
18.55 
45.33 
+/- 
24.43 
7.19 +/- 
16.40 
4.4 Discussion 
 
The Tobago cohort is comprised of two subgroups, Tobago biopsies and Tobago 
Prostatectomies.  The data presented here, from both groups, shows that HHV-8 
protein expression can be detected in the prostates of men from Tobago.  Viral protein 
expression is not present in the cancer cells, but in the surrounding tissues (Figure 14).   
 
 
73
4.4.1 Tobago Biopsy subgroup 
Among the Tobago biopsy subgroup, no viral antigen expression was seen in the 
seronegative subjects (table 4).  Viral antigen expression, in the seropostitive subjects, 
was similar to what we saw in the MACS cohort (see chapter 2).  In the MACS cohort 
we saw at least one viral antigen expressed in 68.9% of the seropositive subjects, and 
in the Tobago biopsy subgroup we saw expression of at least on viral antigen in 75% of 
the seropositive subjects.   
We found no significant difference in inflammatory infiltrates, based on CD68 
expression, between the seropositive and the seronegative subjects (table 5).  This 
could be a product of our N being so low.  We only had 7 seronegative and 12 
seropositive patients; perhaps if we were able to increase the N, we would find 
significant difference.  It also may be explained by the cancer.  It is well documented 
that cancer causes inflammation and inflammation is measured by CD68 infiltrates.  
Another possible explanation is that these men were undergoing a biopsy of the 
prostate.  That is a traumatic injury to the organ, injury is a possible cause of 
inflammation.  For these reasons, it is not unreasonable that we have not found a 
difference in inflammation, as marked by CD68 staining, in the seropositive and 
seronegative prostates of the Tobago biopsy subgroup.   
4.4.2 Tobago Prostatectomy Subgroup 
In this subgroup, all but three subjects expressed viral antigen.  There was antigen 
positive staining detected in the seronegative subjects, six in total.  In five of the six 
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seronegative subjects that expressed viral antigen, both K8.1 and LANA-1 were seen.  
This suggests that those patients who stained positive for viral antigen but were 
seronegative possessed titers that were below the detection limit for the serological 
assay we used.  All of the seronegative patients underwent re-testing to reconfirm that 
they were seronegative.  Upon retesting, the subjects remained negative by the 
serological test.  Since the majority of the seronegative subjects expressed both viral 
proteins, we believe them to be HHV-8 positive by antigen expression, but with low 
HHV-8 antibody titers.  Recent studies in our laboratory have shown that individuals can 
sero-revert (unpublished data, McDonald, Bunker and Jenkins).  Presumably sero-
reversion is a result of the antibody titers falling below the sensitivity of the serological 
assay.  
Within the prostatectomy subgroup, LANA-1 and K8.1 were seen together in 12 of the 
13 patients that were positive for LANA-1.  This suggests that both types of infection are 
present in these prostates.  These data complement what we saw in both the Tobago 
biopsy subgroup and the MACS cohort.   
LANA-1 appeared to be expressed predominantly in the endothelial cells of the 
prostate.  K8.1 appeared to be expressed predominately in what looked like 
macrophages.  These data also complement what we saw in the MACS cohort.  Due to 
difficulties in double staining the same cell by IHC, we were unable to stain the K8.1 
positive cells for the macrophage marker.  This difficulty was also a problem for 
determining if the LANA-1 positive cells were indeed endothelial cells.  Antigen retrieval 
time was also a problem for LANA-1 positive cells.  In order to see the LANA-1 stain, we 
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need to do a 40 min retrieval.  This made it almost impossible to see any membrane 
bound or cytoplasmic proteins.   
We were able to determine the percentage of positive cells for each marker.  This 
allowed us to determine that there was a significant difference in viral antigen 
expression within the same patient between cancerous and non-cancerous areas of the 
prostate.   Viral protein expression, both LANA-1 and K8.1, was higher in the cancerous 
sections versus the non-cancerous sections.  When viral protein expression was 
present we also observed an increased macrophage infiltrate.  This suggests that in 
areas of cancer there is a higher amount of viral replication, due to K8.1 presence, and 
an increased immune infiltrate.   
We also showed that within the same patient, the areas with cancer exhibited an 
increased immune infiltrate, both CD20 and CD68, over the areas that were cancer-
free.  The increased immune infiltrate could be a result of just the cancer or a 
combination of the cancer and the virus.  Our earlier results with the cancer-free 
prostates of the MACS cohort suggest that at least some of the increased in immune 
infiltrate is due to the presence of the virus.   The difference in antigen expression seen 
in the cancer vs. non-cancer can aid in explaining our hypothesis that the virus infects, 
establishes a chronic inflammation and sets up a microenvironment that aids in tumor 
development.  We found an increase in macrophage staining in the Tobago cohort over 
what we saw in the MACS.  This may be due to the MACS men having AIDS.   
We also determined that the gp130 high risk allele exhibited an increased macrophage 
infiltrate in the non-cancer subjects when compared to the gp130 low risk allele in the 
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non-cancer subjects.  This suggests that the gp130 high risk allele is associated with an 
increased inflammation.  
We did see more macrophage staining in the Tobago cohort than in the MACS cohort.  
We believe that this is due to the MACS cohort being immunocompromised in that those 
men had AIDS.   
It is possible that our increased staining seen in the cancerous sections of the Tobago 
prostatectomy group is simply due to the cancer being present.   However, a positive 
association between prostatic inflammation and onset of cancer has been reported 8, 
meaning that the inflammation in some cases occurs before the cancer.  It is also 
possible that the men possessing the high risk gp130 genotype are at a later stage in 
their cancer development.  This may be why we see greater inflammation in the gp130 
high risk genotype men. 
Further discussion of this cohort, as well as, comparisons between the cohorts will be 
done in chapter seven of this dissertation.   
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5.0 Chapter Five:  Detection of HHV-8 in the Cancerous Prostates of Men from the 
United States.  PUCC Cohort. 
5.1 Introduction 
 
It has been shown that HHV-8 is present in cancerous prostates and produce both lytic 
and latent proteins (see Chapter 4).  We showed a difference in inflammation, within the 
same patient, between the areas with and without cancer.  The study described in 
Chapter 4 was done with subjects from Tobago where we saw an interaction between a 
genetic polymorphism in gp130 and HHV-8 infection that produced a 3.1 odds ratio for 
prostate cancer.  The study described in this Chapter was designed to see if, in a 
population where the gp130 polymorphism and HHV-8 infection are less prevalent, we 
see interactions resulting in increased cancer risk.    
Recent studies from our laboratory have shown seroprevalence of HHV-8 in cohorts of 
men with prostate cancer from the U.S. to be 17-20% 7,111.  This seroprevalence is 
lower than the 40% seen in Tobago 7.    The Hoffman et. al. 7 paper was the first to be 
published; this study looked at men from Tobago and the U.S.  It suggests that HHV-8 
plays a role in the development of prostate cancer.  They found that HHV-8 
seropositivity is elevated in men with prostate cancer when compared to the controls.   
The following paper, Sutcliffe and colleagues found an inverse association between 
HHV-8 seropositivity and prostate cancer (OR, 0.70; 95% CI, 0.52-0.95).  They stated 
that HHV-8 may serve to protect against prostate cancer 112.   The most recent paper 
looked at HHV-8 seroprevalence in two case-control studies; one cohort consisted of 
 
 
78
white men from Bologna, Italy and the other cohort was comprised of African American 
men from Washington, D.C 111.  This study found a seroprevalence among cases of 
40% in Italy and 17% in Washington D.C.  The conclusion of this study was that HHV-8 
seroprevalence was not significantly different in either study, but the cases exhibited a 
lower seroprevalence.  They stated:  “ these data imply that HHV-8 is not a major 
prevalent cause of prostate cancer” 111.   
In this study, we strived to replicate our study from Tobago with the U.S. cohort.  We 
performed immunohistochemistry on cancerous prostates from 39 men from the PUCC, 
Pittsburgh Urologic Cancer Cohort.  Ninteen men were HHV-8 seropositive and 20 men 
were HHV-8 seronegative.  Serial paraffin sections were examined for expression of 
viral proteins to determine if HHV-8 can be found in cancerous prostates.  These 
proteins were LANA-1, a protein expressed during latency, and K8.1, a viral protein 
expressed during lytic replication.  We also wanted to see if localized inflammation was 
present determined by using a macrophage/monocyte marker, CD68, and a B-cell 
marker, CD20.   
5.2 Methods 
5.2.1 Immunohistochemistry 
See section 2.4.1 of Chapter 2. 
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5.2.2 Prostate Tissue 
The PUCC, Pittsburgh Urological Cancer Cohort, provided our laboratory with serum 
samples from 508 men for HHV-8 serological testing.   From those 508 men, came the 
39 we identified for this study. 
5.2.3 Percentage of Positive Cells 
See sections 3.4.2 and 3.4.4.   
5.2.4 Statistics 
See section 4.2.4 
5.2.5 gp130 Genotyping 
See section 4.2.6 
5.3 Results 
The PUCC cohort represented men with prostate cancer from the United States where 
the tissue was taken at surgery or biopsy.  All subjects were deemed cancerous by 
pathological examination.  Among the men tested, 61 (12.01%) were seropositive for 
HHV-8 upon duplicate serological testing.  The seropositive men were age and race-
matched to seronegative men.  Table 12 shows the age breakdown of the cohort. The 
race breakdown was 61.5% (24/39) Caucasian and 38.5% (15/39) unknown. 
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Tables 13 and 14 list the subject characteristics and selected protein expression of the 
seropositive and seronegative subjects respectively.  In figure 18 the percentage of 
seropositive men who showed antigen expression of at least one protein, LANA-1or 
K8.1 is shown, while figure 19 shows a representative sample of LANA-1 and K8.1 
staining.   
Table 12: Age Range of PUCC Cohort 
Age N Percent 
50-54 10 25.68 
55-59 12 30.8 
60-64 9 23.1 
65-69 4 10.3 
70-74 4 10.3 
The Table shows the ages of the PUCC cohort subjects. 
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Table 13: Subject Characteristics and Protein Expression of Seropositive PUCC Subjects 
Seropositive lana %lana k8.1 %k8.1 CD68 %CD68 CD20 CD20% 
1 - 0 + 42.27 + 32.09 + 22.45 
2 + 2.58 + 50.35 + 38.52 + 22.23 
3 - 0 + 8.68 + 88.48 + 17.25 
4 + 0.8 - 0 + 51.19 + 3.15 
5 - 0 + 3.27 + 12.62 + 4.11 
6 - 0 + 78.84 + 67.45 + 22.97 
7 - 0 - 0 + 54.86 + 6.78 
8 + 0.68 + 7.94 + 62.19 + 19.64 
9 + 1.07 + 66.99 + 31.18 + 39.57 
10 + 1.31 - 0 + 15.79 + 5.23 
11 + 0.69 + 27.53 + 6.82 + 27.99 
12 + 2.48 + 50.43 + 8.29 + 24.56 
13 + 1.06 + 25.22 + 4.65 + 5.78 
14 - 0 + 0.42 + 91.1 + 60.51 
15 - 0 + 30.53 + 37.85 + 59.61 
16 - 0 + 25.78 + 16.35 + 34.34 
17 - 0 - 0 + 59.09 + 18.74 
18 + 0.54 + 50.87 + 7.28 + 3.33 
19 - 0 - 0 + 38.67 + 22.99 
The table shows the characteristics of the seropositive PUCC subjects.  %protein 
means the number of positively stained cells in the specified grid. (see chapter 3). 
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Table 14: Subject Characteristics and Protein Expression of Seronegative PUCC Subjects 
Seronegative lana %lana k8.1 %k8.1 CD68 %CD68 CD20 CD20% 
20 + 0.79 + 26.04 + 14.78 + 16.18 
21 - 0 - 0 + 68.44 + 44.44 
22 - 0 + 8.93 + 44.13 + 18.22 
23 + 6.17 + 27.37 + 41.12 + 44.26 
24 + 7.55 + 88.3 + 61.78 + 64.92 
25 + 0.86 + 8.36 + 30.2 + 11.19 
26 - 0 - 0 + 40.65 + 43.29 
27 - 0 - 0 + 34.49 + 37 
28 - 0 - 0 + 53.02 + 37.94 
29 - 0 - 0 + 23.16 + 19.78 
30 - 0 - 0 + 22.99 + 20.19 
31 - 0 - 0 + 60 + 33.99 
32 - 0 - 0 + 10.36 + 12.32 
33 - 0 - 0 + 54.89 + 70.62 
34 + 1.33 + 39.63 + 45.66 + 49.01 
35 - 0 - 0 + 62.8 + 55.57 
36 - 0 - 0 + 58.65 + 48.61 
37 - 0 - 0 + 24.69 + 11.67 
38 - 0 - 0 + 31.49 + 38.54 
39 - 0 - 0 + 3.04 + 2.11 
The table shows the characteristics of the seronegative PUCC subjects.  %protein 
means the number of positively stained cells in the specified grid. (see chapter 3). 
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 Figure 18: PUCC Cohort HHV-8 Protein Expression 
Figure 18 shows that 84.6% of the seropositive subjects expressed at least one protein 
(LANA-1 or K8.1) and that 15.4% of the seropositive subjects expressed no viral 
proteins. 
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Figure 19: HHV-8 Proteins in the Prostate Tissue of Men from the PUCC Cohort 
A. Shows staining for LANA-1 at 400x.  B Shows serial section stained with normal rat 
at 400x. C. Shows staining for K8.1 at 400x. D. Shows serial section stained with 
normal mouse at 400x. 
 
Among the HHV-8 seropositive subjects, viral protein expression was detected in 
multiple regions of each section, but not in the cancer.  Some of the subjects show both 
lytic and latent expression in the stained regions, while other regions contained only 
latent or only lytic.  Six of the seronegative subjects showed protein expression (Table 
15) with K8.1 expression the more predominate protein expressed.  Of the 14 samples 
that expressed LANA-1, 12 or 85.7% expressed K8.1.   
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In order to determine the amount of inflammation in each prostate, individual sections 
were stained with antibodies directed against CD68, a macrophage marker and CD20 a 
B-cell marker.  Representative samples can be seen in Figure 20.    To determine the 
total number of positive cells we used a semi-quantative image analysis developed and 
validated in our laboratory and described in sections 3.4.2 and 3.4.4 of this dissertation.  
The number of positive cells was adjusted for total cell number.  Those values are 
shown in Tables 13 and 14.   
We asked whether differences in percentages of CD68 and CD20 positive cells were 
seen between HHV-8 antigen positive and HHV-8 antigen negative sections.  No 
difference was found in CD68 and CD20 expression based on viral antigen status 
(p>0.05; Mann-Whitney U)   
We next asked whether differences were seen between LANA-1 positive and LANA-1 
negative sections and K8.1 positive and negative sections with respect to CD68 and 
CD20 infiltrate.  Again we found no differences between LANA-1 positive and negative 
sections or K8.1 positive and negative sections (p>0.05; Mann-Whitney U) 
We have unpublished data on the R148G polymorphism (discussed in section 4.1 and 
section 1.7 table 2) from the Caribbean island of Tobago.  That same gp130 SNP 
analysis was performed on a United States cohort, a combination of MACS and PUCC 
men, 263 in total.  Table 15 shows the data from the SNP analysis.  A significant 
p=0.000 difference (chi-square analysis) between the U.S. and Tobago cohorts is seen. 
The G genotype was present in at least one allele in 71.4% of Tobago men and 29.7% 
of US men.   
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The PUCC cohort was tested for gp130 allele status.  Table 16 shows the breakdown of 
allele status in the PUCC cohort.  There were no homozygous high risk genotypes 
(G/G) seen and only 27% of the men were heterozygous (C/G).   We asked whether 
gp130 allele status resulted in increased inflammatory markers.  No difference was 
seen in inflammatory markers between the gp130 heterozygous and C/C homozygous 
low risk allele. 
Table 15: Comparison of Tobago and United States gp130 SNP analyses 
 United States 
N                     % 
Tobago 
N                    % 
C/C 185            70.4 335               27.5 
C/G 68              25.9 598              49.1 
G/G 10                3.7 284              23.4 
 
Table 16: gp130 Allele Status of PUCC Cohort 
 N                     % 
C/C 27                    73 
C/G 10                    27 
G/G 0                     0 
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Figure 20: Immune Infiltrate Staining in PUCC Cohort 
Figure 20 PUCC Cohort Staining. A. Shows staining for CD68 at 400x. B. Shows serial 
section stained with normal goat serum. C. Shows staining for CD20 at 400x.  D. Shows 
serial section stained with normal mouse serum. 
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5.4 Discussion 
 
This cohort was comprised of men from the United States who have prostate cancer.  
We did see viral antigen expression in the seronegative subjects.   Six out of the 20 
seronegative subjects expressed viral proteins (see table 14).  Of those six, five of them 
expressed both K8.1 and LANA-1.  This, as with the Tobago prostatectomy subgroup, 
may be a result of the subjects HHV-8 antibody titer being below the detection limit of 
the serological assay.  Subjects underwent re-testing to verify that they were in fact 
seronegative.  Upon retesting, subjects remained seronegative.  As with the Tobago 
prostatectomy subgroup, the majority of the subjects that expressed viral protein 
expressed both.  We believe them to be seropositive by protein expression and below 
the detection limit of the serological assay. 
Within this cohort LANA-1 and K8.1 expression were seen in the majority (12/22) of the 
subjects expressing antigen.  This suggests that both types of infection, latent and lytic, 
were present.   
As with both other cohorts, LANA-1 expression was seen primarily in the endothelial 
cells of the prostate and K8.1 was seen primarily in what appeared to be the 
macrophages.  As discussed previously, the difficulties of double staining sections 
prohibited us from verifying these observations.  Figure 19 shows K8.1 staining in the 
endothelial cells; this is not edge artifact the picture was taken in the center of the slide.   
We were able to determine total number of positive cells for each antigen.  These 
results showed no differences between the inflammatory markers, CD68 and CD20, 
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with respect to subjects that were antigen positive, subjects that were LANA-1 positive, 
and subjects that were K8.1 positive.  No difference was seen based on gp130 allele 
status.   
We found a lower HHV-8 seroprevalence than the three other studies out of our 
laboratory.  We saw a seroprevalence of 12.01%, where as the other studies found a 
seroprevalence of 17-20% in prostate cancer cases.  Our n=508 was larger than the 
other studies.  This could be why our seroprevalence was lower.  The study conducted 
on the men from Italy and Washintgon D.C. involved men with advanced metastatic 
prostate cancer; this could be a confounding issue in their study.  In our study, the men 
did not have such advanced stages of cancer.  Also, the study done in Washington D.C. 
involved more African American men, this may have added to the higher 
seroprevalence seen in that study.  African Americans have a higher seroprevalence for 
HHV-8.     
We saw in this cohort, as we did in the Tobago cohorts, that HHV-8 is present in the 
prostates of seropositive men.  However, the differences in inflammation between 
seropositive and seronegative were not seen in the PUCC cohort.  This could be due to 
the design of the PUCC study.  We were able to have areas with and without cancer 
from the same patient in the Tobago Prostatectomy subgroup.  This allowed us to 
compare differences in inflammation within the same patient.  Those tissues were not 
available to us with the PUCC cohort.  This could explain why we did not see the 
differences in inflammation in the PUCC cohort, we did not have tissue that was cancer 
free.   
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The gp130 genotype is not as prevalent in the U.S. as it is in Tobago (table 15).  We 
know from the Tobago cohort data that HHV-8 combined with the high risk G/G gp130 
polymorphism produces an odds ratio for prostate cancer of 3.1.  The high risk 
polymorphism is found in 3.7% of the U.S. cohort compared to the 23.4% seen in the 
Tobago cohort.    Also, in the Tobago cohort, the gp130 high risk polymorphism was 
associated with an increase inflammation in the areas of non-cancer (section 4.3.4, 
table 10).  This suggests that the absence of the high risk gp130 polymorphism in the 
U.S. population explains the lack of association seen in the U.S.  
Further discussion of this cohort, as well as, comparisons between the cohorts will be 
done in chapter seven of this dissertation. 
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6.0 Chapter Six:  Functional Characterization of the gp130 R148G Polymorphism 
6.1 Introduction 
 
The gp130 cytokine receptor is a member of the hematopoietic cytokine receptors 113.   
It is expressed on almost all cell types 25.  These receptors have an extracellular region, 
a single transmembrane portion, and a cytoplasmic domain.   There is a conserved 
domain on the gp130 receptor that is characterized by four positionally conserved 
cystine residues in its amino terminal end and a WSXWS (W=tryptophane, S=serine, 
X=non conserved amino acid) motif at its carboxyl end 114.   
The gp130 receptor signals through the Janus kinase- signal transducer and activator of 
transcription (JAK-STAT) pathway.  Of the various cytokine receptors, gp130 is the 
signal transducer for several ligands.    It signals for IL-6, IL-11, and OSM to name a 
few.  Binding of these cytokines to their respective binding receptors leads to binding of 
gp130.  Once gp130 is bound, JAK is activated causing downstream signaling of 
STATs.   
In order for downstream signaling to occur through gp130, the cytokine must first bind to 
its own receptor.  For example, IL-6 and IL-11 must first bind to a nonsignaling α 
receptor, and then that complex binds to gp130 25.  In the case of IL-6, two molecules 
bind to two of the IL-6Rαs, which then binds a homodimer of gp130, forming a 
hexameric complex 115.  IL-11 uses the same pattern, two molecules of IL-11 bind to two 
molecules of IL-11Rα, which then bind to a homodimer of gp130 25.  In contrast, the 
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cytokine OSM does not have a nonsignaling receptor; it binds to the heterodimer of 
OSMR and gp130.   
For the purposes of this dissertation we will focus on the relationships of IL-6, IL-11 and 
OSM to gp130.  The objectives of this study were to determine if the gp130 R148G 
polymorphism affects the function of the gp130 protein.  To this end, we will determine if 
the polymorphism has an effect on growth of lymphoblastoid B cell lines (LCLs) 
developed from Tobago men.  We have the following LCL lines: 3 homozygous low risk, 
5 heterozygous, and 7 homozygous high risk.  We will also evaluate the STAT-3 
activation induced by stimulation with IL-6, IL11, and OSM. 
6.1.1  IL-6 
As described above, IL-6 forms a 2:2:2 hexameric complex with gp130 and IL-6Rα 116.  
IL-6 downstream signaling activates JAKs which activate STAT-3.  The activated STAT-
3 homodimers translocate into the nucleus116.  IL-6 is a B-cell growth factor that creates 
an autocrine feedback loop 116.   
6.1.2 IL-11 
IL-11 also forms a hexameric complex with gp130 and IL-11Rα 25.  IL-11 downstream 
signaling activates STAT-3 in a similar fashion as IL-6.  Studies have shown that IL-11 
is a potent anti-inflammatory cytokine; it down regulates macrophage effector function 
by inhibiting TNFα 117.   
 
 
93
6.1.3 OSM 
Oncostatin M uses one OSMR and one gp130 molecule to exhibit its downstream 
signaling 118.  OSM is a 28kDa protein that is known to inhibit growth in several types of 
cells, such as tissue tumor cells, melanoma cells, and plasmacytoma cells 118.  
However, OSM is known as an autocrine growth factor for AIDS-associated Kaposi’s 
sarcoma cells.  Downstream signaling of OSM involves the JAK-STAT pathway as well 
113. 
6.2 Methods 
 
6.2.1 Cell Culture 
Cells were maintained in RPMI 1640 with 10000 U/ml Pen/10000ug/ml Strep and 10% 
FBS.  For cytokine experiments cells were plated 24 hours before in AIM V media.   
6.2.2 Generation of LCLs 
 
LCLs were generated by in vitro transformation of peripheral B cells with Epstein Barr 
Virus (EBV).  Briefly, 5x105 PBMCs in 1 ml of B-cell media [BCM; 500ml of RPMI 1640, 
10% FBS, 5.5ml of 100x L-glutamine (Gibco Cat. # 10-040-CV), 10000 U/ml 
Pen/10000ug/ml Strep (Gibco),100mM Sodium Pyruvate (Gibco),100x MEM Non-
essential amino acids (Gibco) , and1M Hepes (Gibco)] were mixed with 1ml of EBV 
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virus supernatant (generously provided by Monica Tomaszewski-Flick,Ph.D, University 
of Pittsburgh) and incubated at 37⁰C for 20 min in a 15ml conical tube.   An additional 8 
mls of BCM was added along with cyclosporine (final concentration 1ug/ml).  The cells 
were plated at 100 ul per well in a 96 well plate (final concentration 5000 PBMCs per 
well of a 96 well plate, approximately 250 B cells).  On day 13, 75ul of BCM was added.  
At 7 weeks, the cells from each well were transferred to a well in a 24 well plate.  At 10 
weeks the cells from each well in the 24 well plate were transferred to a T-25 flask.   
Ten of the fifteen LCLs were made by the same protocol in the laboratory of Dr. 
Giovanna Rappocciolo at the University of Pittsburgh Graduate School of Public Health. 
6.2.3 Growth Curves 
Growth curves of the LCLs were performed using a 4% trypan blue solution (in 
phosphate buffered saline ph 7.2)  exclusion cell count on a hemocytometer.   Cells 
were diluted in the trypan blue solution at 1:100 and counts were taken.  Trypan blue 
stains dead cells blue, alive cells remain unstained.  A count of both alive cells and 
dead cells was taken at each time point.   Cells were then plated at 1x104/well in a 96 
well plate in AIM V media and incubated at 37⁰C overnight.  The next day each well was 
either left untreated or given 25ng of either rhIL-6, rhIL-11 or rhOSM (R&D systems Cat. 
# 206-IL, 218-IL, and 295-OM respectively). Cells from three wells for each treatment 
were collected and counted at 0, 12, 24, 36, 48, 60, and 72 hours post-treatment.  
Graphs were plotted on GraphPad Prism 4 software. 
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6.2.4 STAT-3 Activation 
STAT-3 activation was measured using the CASE Cellular Activation of Signaling ELISA 
(Super Array, Cat. # FE018) per manufacturer’s instructions.  Briefly, cells were seeded 
in a 96 well plate at 1.5x104cells/well in AIM V media 24 hours before experiment.  
Wells received either 0, 12.5, 25, or 50ng rhIL-6.  At 0, 15, 30, 45, and 60 minutes post 
treatment, cells were fixed with 8% formaldehyde fixing buffer in 1xPBS.  Wells were set 
up in mirror images with half of the plate being treated with anti-PSTAT-3 antibody 
(which recognizes only phosphorylated (activated) STAT-3) and half of the plate treated 
with anti-STAT-3 antibody (which recognizes both non-phosphorylated and 
phosphorylated STAT-3) and incubated for 1 hour at room temperature.  The wells were 
extensively washed and then treated with secondary antibody at room temperature for 1 
hour.  Following incubation with the secondary antibody, substrate was added to each 
well and colorimetric detection performed at 450nm on an ELISA plate reader.  
Determination of relative cell number was done as per the kit.  To determine the relative 
extent of STAT-3 phosphorylation, normalization of the P-STAT-3 antibody to the STAT-
3 antibody for the same experimental control was done.  Results were plotted using 
GraphPAD Prisim 4 software. 
6.2.5 gp130 Genotyping 
See section 4.2.6. 
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6.3 Results 
 As part of our ongoing study in Tobago, we constructed LCLs from 15 Tobago men.  
The gp130 genotype of each LCL was confirmed by Dr. Ferrell’s laboratory (data not 
shown).  We first wanted to determine the effect of IL-6, IL-11, and OSM on cell growth 
of the different LCLs.  We used trypan blue exclusion to assess the effects of 25ng of 
each cytokine on cellular proliferation and compared those effects to untreated cells, we 
used 25ng because that most closely resembles physiologic  level IL-6.   
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Tobago Low Risk Lines Response to 25ng rhIL-11
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(Figure 21 Continued Below) 
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C. 
Tobago Low Risk Lines Response to 25ng rhOSM
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D. 
Tobago Homozygous Low Risk Lines Response to all Cytokines
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Figure 21: Tobago Low Risk Lines 
Growth Curve analysis of Tobago Homozygous Low Risk Lines response to  A) 25ng IL-
6 B) 25ng IL-11 C) 25ng OSM and D) 25ng of IL-6, IL-11, and OSM.  Cells had 25ng of 
cytokine added at 0 hours and time points were taken every 12 hours.  Cell counts were 
taken and cell numbers were plotted per milliter. 
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A. 
Tobago Heterozygous Lines response to 25ng rhIL6
0 12 24 36 48 60 72
0
50000
100000
150000
200000
250000
T5 none
T7 none
T8 none
T9 none
T10 none
T5 IL6
T7 IL6
T8 IL6
T9 IL6
T10 IL6
Hours
C
el
ls
/m
L
 
B. 
Tobago Heterozygous Line Response to 25ng rhIL-11
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(Figure 22 Continued Below) 
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C. 
Tobago Heterozygous Lines Response to 25ng rhOSM
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D. 
Tobago Heterozygous Lines Response to All Cytokines
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Figure 22: Tobago Heterozygous Lines 
Growth Curve analysis of Tobago Heterozygous Lines response to  A) 25ng IL-6 B) 
25ng IL-11 C) 25ng OSM and D) 25ng of IL-6, IL-11, and OSM.  Cells had 25ng of 
cytokine added at 0 hours and time points were taken every 12 hours.  Cell counts were 
taken and cells per milliter were plotted. 
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A.  
 Tobago High Risk Lines Respons to 25ng rhIL6
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B. 
Tobago High Risk Lines Response to 25ng rhIL-11
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(Figure 23 Continued Below) 
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C. 
Tobago High Risk Lines Response to 25ng rhOSM
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D. 
High Risk Tobago Lines All Cytokines
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Figure 23: Tobago High Risk Lines 
Growth Curve analysis of Tobago Homozygous High Risk Lines response to  A) 25ng 
IL-6 B) 25ng IL-11 C) 25ng OSM and D) 25ng of IL-6, IL-11, and OSM. .  Cells had 
25ng of cytokine added at 0 hours and time points were taken every 12 hours.  Cell 
counts were taken and cell number was plotted per milliter. 
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The cytokine growth curves from the Tobago LCLs showed that all three genotypes 
exhibited cellular proliferation in the presence of 25ng rhIL-6.  The homozygous high 
risk alleles exhibited a 250% increase over the homozygous low risk lines and a 100% 
increase over the heterozygous lines in response to 25ng rhIL-6 (Figures 21-23).  The 
heterozygous lines exhibited a 150% increase over the homozygous low risk lines in 
response to 25ng of rhIL-6 (Figure 22 B, C).  In contrast, none of the lines showed 
increased proliferation to the addition of either IL-11 or OSM, suggesting that the 
R148G polymorphism is IL-6 specific. 
We next asked whether the gp130 R148G polymorphism affected downstream gp130 
signalling as measured by STAT-3 phosphorylation.  Each LCL was stimulated with 0, 
12.5, 25, and 50 ng of rhIL-6, and cells were collected at various time points as 
measured for STAT-3 activation.   The following figures show the results. 
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 Tobago Homozygous Low Risk Lines: 0ng IL-6
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(Figure 24 Continued Below) 
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C. 
Tobago Low Risk Lines: 25 ng IL-6
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D. 
Tobago Low Risk Lines: 50 ng IL-6
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Figure 24: Tobago Homozygous Low Risk Lines STAT-3 Activation 
Experiments were done with 1000 cells. A) Shows the C/C lines ratio of activated P-
STAT-3 or Total STAT-3 per cell-0ng IL-6. B) shows activation at 12.5ng IL-6 C) shows 
activation at 25ng IL-6 D) Shows activation at 50ng IL-6. 
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A. 
Tobago Heterozygous Lines: 0ng IL-6
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B. 
Tobago Heterozygous Lines: 12.5ng IL-6
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(Figure 25 Continued Below) 
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C. 
Tobago Heterozygous Lines: 25 ng IL-6
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D. 
Tobago Heterozygous Lines: 50ng IL-6
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Figure 25: Tobago Heterozygous Lines STAT-3 Activation 
Experiment were done with 1000 cells. A) Shows the C/G lines ratio of activated P-
STAT-3 or Total STAT-3 per cell-0ng IL-6. B) shows activation at 12.5ng IL-6 C) shows 
activation at 25ng IL-6 D) Shows activation at 50ng IL-6. 
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A. 
Tobago High Risk Lines: 0ng IL-6
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Tobago High Risk Lines: 12.5ng IL-6
0 15 30 45 60
0.0
0.5
1.0
1.5
2.0
T13 0ng
T14 0ng
T17 0ng
T18 0ng
T19 0ng
T20 0ng
T13 12.5ng
T15 12.5ng
T17 12.5ng
T18 12.5ng
T19 12.5ng
T20 12.5ng
Minutes
PS
TA
T3
:S
TA
T3
 
(Figure 26 Continued Below) 
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C. 
 Tobago High Risk Lines: 25ng IL-6
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D. 
 Tobago High Risk Lines: 50ng IL6
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Figure 26: Tobago Homozygous High Risk Lines STAT-3 Activation 
Experiment were done with 1000 cells. A) Shows the G/G lines ratio of activated P-
STAT-3 or Total STAT-3 per cell-0ng IL-6. B) shows activation at 12.5ng IL-6 C) shows 
activation at 25ng IL-6 D) Shows activation at 50ng IL-6. 
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All of the LCLs showed a dose response to the rhIL-6.  The homozygous low risk lines 
showed a weak double peak pattern, with peaks at 15 and 45 minutes.  This can best 
be seen in figure 4D at 50 ng of rhIL-6, negligible activation.   The heterozygous lines 
exhibited a drop in activation with marked increase at 15 minutes. This is most visible at 
50ng of rhIL-6 in figure 5D.  The high risk lines demonstrated a high level of activation 
from 15-45 minutes, seen best in figure 6D. 
6.4 Discussion 
 
 
Figure 27: gp130 Binding Regions. 
IL-6 is represented in green. IL-11 is represented in red. OSM is represented in orange. The 
yellow arrow indicates where the gp130 R148G polymorphism is located. 
The GG genotype, referred to here as the Tobago homozygous high risk, was 
associated with elevated prostate cancer risk, OR=1.5 (95% CI 0.98-2.32) in logistic 
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regression and both gp130 and HHV-8 seropositivity were independently associated 
with prostate cancer.  Further exploration of the six genotype-HHV-8 combinations 
revealed an OR of 3.1 (95% CI 1.2-8.1 p=0.022) for prostate cancer in men who are 
HHV-8 seropositive and have the GG genotype, compared to the lowest risk group, who 
are HHV-8 negative and have the CC genotype (Section 1.7 Table 2).  We 
hypothesized that this effect of gp130 genotype may be mediated through its role in IL-6 
signaling.   
We have shown that the R148G polymorphism in the gp130 signaling receptor is 
functional, in that it exhibits an increased proliferative response on LCLs from men with 
the G/G genotype.  In testing the LCL’s growth potential when 25ng of rhIL-6, rhIL-11, 
and rhOSM were added, we saw that the proliferative response appears to be specific 
to rhIL-6.  This suggests that the polymorphism found in gp130 is affecting the binding 
region of IL-6.   Gp130 has six binding regions 119.  The gp130 cytokines utilize regions 
D1-D3 to bind, IL-6 uses D2, IL-11 uses D3, and OSM uses D1 (see Figure 27) 119.  The 
D1 binding region uses the B and D helical faces of the protein;  the polymorphism is 
located at the end of the D1 binding region approximately 40 amino acids below the D 
helical face 119.   This may be why the D1 binding region is not affected.  However, our 
data suggest that the polymorphism may affect the D2 region of gp130.   Since the 
polymorphism is located below the faces that bind in the D1 region, it is possible that 
the amino acid switch caused by the polymorphism is altering the D2 binding site.  This 
could explain why IL-11 and OSM do not affect the growth of the LCLs in the same 
manner that IL-6 does.     
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We have also shown that each genotype shows a distinctly different PSTAT-3:STAT3 
response to rhIL-6 at 25ng.  The low risk allele shows a double peak pattern with 
relatively weak increases in activation at 15 and 45 minutes.  The heterozygous allele 
shows a drop early followed by strong activation after 15 minutes.  While the high risk 
allele shows immediate strong activation that remains for 30 minutes.    
Together the growth curve and STAT3 activation data suggest that the high risk G/G 
genotype confers a growth advantage over the other the genotypes in response to IL-6.  
The continuous activation of STAT-3 beginning at 15 minutes and continuing until 45 
minutes suggests that STAT-3 in the high risk allele is more easily activated.  Constant 
activation of STAT3 is known to confer a growth advantage in the activated B-cell 
subtype of diffuse large B-cell lymphomas 120.   
The observation that IL-11 and OSM, a cytokine that shares the gp130 homodimer as 
its signaling receptor with IL-6, did not confer a growth advantage, suggests that this 
effect is IL-6 specific.  We believe that the R148G polymorphism is differentially 
functional which may explain the increased risk associated with the high risk 
polymorphism.  We have shown that the polymorphism infers a growth advantage to B-
cells to which IL-6 has been added.  Further functional studies are needed to elucidate 
the role the polymorphism plays in the inflammatory response, HHV-8 infection and KS. 
Further discussion of this can be found in chapter seven of this dissertation.  
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7.0 Chapter Seven:  Discussion 
7.1 Summary 
 
While the causation of prostate cancer remains unknown, Nelson and colleagues have 
suggested a sexually transmitted agent may be a possible cause 9.  It is thought that a 
man acquires a sexually transmitted agent which sets up a chronic infection that leads 
to chronic inflammation and ultimately prostate cancer (section 1.8, figure 3).   Previous 
work in our laboratory shows that HHV-8 infection was elevated among men from 
Tobago with prostate cancer compared to age-matched controls (P=0.003, OR 2.24, 
95% C.I. 1.29-3.90) (section 1.6,Table 1) 7.  The GG genotype of the gp130 IL-6 
signaling receptor was also associated with elevated prostate cancer risk, OR=1.5 (95% 
CI 0.98-2.32) in logistic regression.  Both gp130 and HHV-8 seropositivity were 
independently associated with prostate cancer.  Upon further exploration of the six 
genotype-HHV-8 combinations, analyses revealed an OR of 3.1 (95% CI 1.2-8.1 
p=0.022) for prostate cancer in men who are HHV-8 seropositive and have the GG 
genotype, compared to the lowest risk group, who are HHV-8 negative and have the CC 
genotype ( section 1.7,Table 2).   
These data led us to explore the association of HHV-8, gp130, and prostate cancer 
further.  We first sought to determine if HHV-8 was in the prostate, because if HHV-8 is 
associated with prostate cancer, then it should be found in the prostates of seropositive 
men.  We used three cohorts, the Multicenter AIDS Cohort Study (MACS), Tobago men, 
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and the Pittsburgh Urologic Cancer Cohort (PUCC).   With each of the cohorts, we 
showed that the virus was present in most of the prostates of seropositive men.  
With the MACS cohort, we analyzed prostates collected at autopsy from 18 men who 
were HIV positive and died with AIDS.  None of these men had prostate cancer as 
determined by histological analysis. Sixteen were HHV-8 seropositive and two were 
HHV-8 seronegative as demonstrated by serology.  Among the HHV-8 seropositive 
cases, seven had KS, four of which were visceral KS (section 2.5.2, table 4).  We 
detected the expression of at least one viral protein in 68.9% of the seropositive 
subjects.  The results clearly demonstrate that HHV-8 infected cells are present in a 
majority of cancer-free prostates of HIV-infected, HHV-8 seropositive men, with the 
detection of viral proteins not caused by the presence of KS since a significant number 
of the samples that were positive for HHV-8 protein expression were from men with no 
evidence of KS.  In fact, there was no correlation between HHV-8 protein expression 
and the presence of KS.  
The Tobago and PUCC cohorts allowed us to use subjects who have been diagnosed 
by histological analysis with prostate cancer.  This allowed us to see if the virus was 
present in the cancer, or in the surrounding tissues. 
The Tobago cohort was comprised of two subgroups, Tobago biopsies and Tobago 
prostatectomies.  These data presented, from both groups, show that HHV-8 protein 
expression can be detected in the prostates of men from Tobago.  Viral protein 
expression is not present in the cancer cells, but in the surrounding tissues (section 
4.3.3, Figure 13).  Among the Tobago biopsy subgroup, no viral protein expression was 
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seen in the seronegative subjects.  Viral protein expression, in the seropostitive 
subjects, was similar to what we saw in the MACS cohort (chapter 2).  In the Tobago 
biopsy subgroup we saw expression of at least one viral protein in 75% of the 
seropositive subjects.   
 The Tobago prostatectomy subgroup allowed us to compare areas with cancer and 
areas without cancer in the same subject.   Within the Tobago prostatectomy subgroup, 
all but three subjects expressed viral protein.  In five of the six seronegative subjects 
that expressed viral protein, both K8.1 and LANA-1 was seen.  All of the seronegative 
patients underwent re-testing to reconfirm that they were seronegative.  Upon retesting, 
the subjects remained negative by the serological test.  Since the majority of the 
seronegative subjects expressed both viral proteins, we believe them to be HHV-8 
positive by protein expression, but with low HHV-8 antibody titers.  Recent studies in our 
laboratory have shown that individuals can sero-revert (unpublished data, MacDonald, 
Bunker and Jenkins).  Presumably sero-reversion is a result of the antibody titers falling 
below the sensitivity of the serological assay.   
We were able to determine the percentage of positive cells for each marker in the 
Tobago cohort.  This allowed us to determine that there was a significant difference in 
viral protein expression within the same patient between cancerous and non-cancerous 
areas of the prostate.   Viral protein expression, both LANA-1 and K8.1, was higher in 
the Tobago cancerous sections versus the non-cancerous sections.  This suggests that 
the virus is influencing the microenvironment in which the tumor develops.  To lend 
further support, we predominately saw LANA-1 in the endothelial cells, where cancer 
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develops.  We are suggesting that the virus aids in tumor development by influencing 
the microenvironment in which the tumor develops. 
The PUCC cohort allowed us to examine a subset of men from the United States.  
Similar to what we saw in the Tobago cohort, among the HHV-8 seropositive subjects, 
viral protein expression was detected in multiple regions of each section, but not in the 
cancer.  Some of the subjects showed both lytic and latent protein expression in the 
stained regions, while other regions contained only latent protein expression and only 
lytic protein expression.  Six of the seronegative subjects showed protein expression 
(section 5.3, Table 14) with K8.1 expression the more predominate protein expressed.   
We were able to quantify the number of cells expressing viral proteins, but found no 
difference between the seronegative and seropositive subjects by Mann-Whitney U.  
As discussed previously, we found that viral gene expression was in the prostatic 
glandular epithelium as well as the infiltrating macrophages in all cohorts.  LANA-1 
expression appeared to be expressed predominantly in the epithelial cells of the 
prostate.  K8.1 appeared to be expressed predominately in what looked like 
macrophages.  Viral IL-6 was stained for only in the MACS cohort, and appeared only in 
what looked like the macrophages.  This suggests that HHV-8 establishes a latent 
infection in prostatic cells and that infiltrating macrophages do not enter the prostate 
latently infected.  The expression of viral lytic genes in the macrophages may indicate 
that the macrophages have either become infected with HHV-8 in the prostate or have 
engulfed cells expressing viral proteins. 
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Next we sought to demonstrate that the presence of the virus in the prostate was 
associated with an increased inflammation.  We used the CD68 macrophage marker to 
determine infiltrates as well as looking at CD20 for B-cell infiltrates.  For the Tobago and 
PUCC cohorts we were able to quantify the number of cells present.  
When we stained the MACS cohort for CD68, we found three distinct patterns of 
macrophage clustering.  The lowest level of CD68 staining had an occasional 
macrophage present in the tissue and was labeled no inflammation (section 2.6, Figure 
7B).  There were two different CD68 staining patterns reflecting increased inflammation.  
Sections that exhibited pronounced areas of staining consisting of several cells in each 
area were labeled as focal staining (section 2.6, Figure 7 D,E).  Sections that exhibited 
many individual or small groups of macrophages located throughout the tissue were 
labeled diffuse (section 2.6, Figure 7 G,H).    Among the seropositive MACS samples, 
20% (1/5) of the samples that did not express viral proteins exhibited inflammation 
compared to 54.5% (6/11) of the samples that expressed at least one viral protein.  
Thus expression of at least one viral protein was associated with increased 
inflammation.   
We found no significant difference inflammatory infiltrates of the Tobago biopsy 
subgroup, based on CD68 expression, between the seropositive and the seronegative 
subjects.  This could be a product of our sample size being so low.  We only had 7 
seronegative and 12 seropositive patients; perhaps if we were able to increase the 
sample size, we would find significance.  It also may be explained by the presence of 
prostate cancer in these biopsies.  It is well documented that prostate cancer is 
associated with increased infiltration, including macrophage infiltrates.  The presence of 
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cancer-related infiltrate in these needle biopsies may mask any effects of viral protein 
expression. Another possible explanation is that these men were undergoing a biopsy of 
the prostate.  That is a traumatic injury to the organ, injury is a possible cause of 
inflammation.  For these reasons, it is not unreasonable that we have not found a 
difference in inflammation, as marked by CD68 staining, in the seropositive and 
seronegative prostates of the Tobago biopsy subgroup.   
With the Tobago Prostatectomy subgroup we were able to analyze areas with and 
without cancer.  We used a Wilcoxon-Signed Ranks test to determine that viral antigen 
expression resulted in an increased macrophage infiltrate.  This suggests that in areas 
of cancer there is a higher amount of viral replication, due to K8.1 presence, and an 
increased immune infiltrate.   
We also showed that within the same patient, the areas with cancer exhibited an 
increased immune infiltrate, both CD20 and CD68, over the areas that were cancer-
free.  The increased immune infiltrate could be a result of just the cancer or a 
combination of the cancer and the virus.  Our earlier results with the cancer-free 
prostates of the MACS cohort suggest that at least some of the increased in immune 
infiltrate is due to the presence of the virus.   
We were also able to determine total number of positive cells for each protein in the 
PUCC cohort samples.  These results showed no differences between the inflammatory 
markers, CD68 and CD20, with respect to subjects that were antigen positive, subjects 
that were LANA-1 positive, and subjects that were K8.1 positive.   
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Taken together, these data suggest that the virus is present in the prostates of 
seropositive men, but it is not in the cancer.  From the Tobago prostatectomy subgroup 
we can surmise that presence of HHV-8 in the prostate can result in an increased 
macrophage infiltrate.  The difference in antigen expression seen in the cancer vs. non-
cancer supports our hypothesis that the virus infects cells in the prostate, establishes a 
chronic inflammation and sets up a microenvironment that aids in tumor development. 
For the Tobago prostatectomy and PUCC cohorts we collected data on the gp130 
R148G polymorphism.  When these data are taken into consideration we find that the 
gp130 high risk allele exhibited an increased macrophage infiltrate in the non-cancerous 
areas when compared to non-cancerous areas from individuals homozygous for the 
gp130 low risk allele in the Tobago subgroup.  This suggests that the gp130 high risk 
allele is associated with an increased inflammation.   
For the PUCC cohort, no difference was seen in immune infiltreate based on gp130 
allele status.  The gp130 genotype is not as prevalent in the U.S. as it is in Tobago 
(section 5.3, table 15).  We know from the Tobago data that HHV-8 combined with the 
high risk G/G gp130 polymorphism produces an odds ratio of 3.1 for prostate cancer.  
The high risk polymorphism is found only in 3.7% of the U.S. cohort compared to the 
23.4% seen in the Tobago cohort.    Also, in the Tobago cohort, the gp130 high risk 
polymorphism was associated with an increased inflammation in the non-cancerous 
areas (section 4.3.4, table 10).  In fact, among the PUCC cohort, there were no 
homozygous high risk (G/G) allele genotypes seen.  This suggests that the lack of 
association between the high risk gp130 allele and inflammation in the U.S. population 
is due to the low prevalence of this allele in the population.  
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Following the observation that the gp130 R148G polymorphism was associated with 
increased inflammation in the Tobago prostatectomy subgroup, we decided to look to 
see if this polymorphism was functional by assessing LCLs developed from men in 
Tobago.  We assessed the effect of rhIL-6, rhIL-11, and OSM on LCL lines representing 
all three genotypes.  All of the Tobago LCLs showed a proliferative dose response to 
rhIL-6 with the homozygous high risk genotype showing the greatest response followed 
by the heterozygous genotype and then the homozygous low risk genotype.  These 
results demonstrate that the R148G polymorphism in the gp130 signaling receptor is 
functional; in that it exhibits an increased proliferative response on LCLs from men with 
the G/G genotype.  In testing the LCL’s proliferative response to 25ng of rhIL-6, rhIL-11, 
and rhOSM, we saw that the response was specific to rhIL-6.  This suggests that the 
polymorphism found in gp130 is affecting the binding region of the gp80/IL-6 complex.   
The R148G mutation is located in the D2 region of the gp130 protein which is known to 
be involved in the binding of gp80/IL-6 and is not believed to be involved with IL-11 and 
OSM binding. This could explain why IL-11 and OSM do not affect the growth of the 
LCLs in the same manner that IL-6 does.     
We have also shown that each genotype shows a distinctly different STAT3 activation 
response to rhIL-6 at 25ng.  The low risk allele shows a double peak pattern with 
increases in activation at 15 and 45 minutes.  The heterozygous allele shows a drop 
early followed by strong activation after 15 minutes.  While the high risk allele shows 
immediate strong activation that remains for 30 minutes.    
Together the growth curve and STAT3 activation data suggest that the high risk G/G 
allele infers a growth advantage to B cells over the other the alleles.  The continuous 
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activation of STAT-3 beginning at 15 minutes and continuing until 45 minutes suggests 
that STAT-3 in the high risk allele is constitutively active.  Constant activation of STAT3 
is known to infer a growth advantage in the activated B-cell subtype of diffuse large B-
cell lymphomas.   
The observation that IL-11, a cytokine that shares the gp130 homodimer as its signaling 
receptor with IL-6, did not infer a growth advantage, suggests that this effect is IL-6 
specific.  We believe that IL-6, through an elevated STAT-3 activation, infers a growth 
advantage, which can lead to aberrant cellular growth.   
These data presented here taken all together show that HHV-8 can be found in the 
prostate.  Expression of viral antigen is associated with an increased macrophage 
infiltrate.  The cancer cells do not contain the virus; the virus is in the surrounding cells.   
The gp130 polymorphism is functional and is associated with viral protein expression 
and increased macrophage infiltrate.  Taken together these data support the hypothesis 
that HHV-8 can serve as a co-factor for the development of prostate cancer by 
establishing a chronic infection which results in chronic inflammation increasing the risk 
of cancer development.  In addition, the data also suggests that genetic factors may be 
important in the overall immune response. 
7.2 Future Directions 
 
Recent studies focusing on monocyte chemoattractant protein-1, MCP-1, found that IL-6 
induces MCP-1 expression in myeloma cells 121.  Nesbit and colleagues have shown 
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that MCP-1 stimulation of monocytes led to tumor formation in nontumorigenic 
melanoma cells 121.  MCP-1 is a member of the CC chemokine family and is known to 
recruit monocytes, NK cells, and certain subpopulations of T-cells.  It is classified as an 
inflammatory chemokine 122.    If IL-6 can induce MCP-1 expression in melanoma, it 
may induce expression in prostate cancer.  We propose that future work look at the 
expression of MCP-1 both in the tissue and in the supernatant from IL-6 induced LCLs 
from Tobago. 
Further experiments on the R148G polymorphism effect on the inflammatory response 
are needed as well.  We propose looking at immune cell migration experiments, in order 
to see if B-cells stimulated with IL-6 can induce migration of immune cells. 
We propose testing the hypothesis that Tobago men with the high risk gp130 
polymorphism have a heightened immune response.  We suggest testing the immune 
response of Tobago men to a vaccine challenge.  It is possible to measure the immune 
response to challenge with an influenza vaccine.  Inoculate the men with the influenza 
vaccine, draw blood every week and measure the immune response.  This will show if 
the high risk men respond faster than the low risk. 
Another option is to look at to mouse for an animal model to study the gp130 
polymorphism.  Mouse gp130 has a proline at the site of the polymorphism, but if a 
mutation that is similar to the one seen in humans is introduced, it may be possible to 
study the effects in a mouse model. 
It is also necessary to increase our genotyping and sample number in subjects from the 
United States.  We believe R148G gp130 polymorphism is involved in the development 
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of prostate cancer in Tobago.  Since the polymorphism has been found at only 3.7% in 
those tested so far in the U.S., it is understandable why we don’t see the association in 
the United States.   
The next step for the gp130 R148G polymorphism is to discern the crystal structure of it 
and IL-6.  If the polymorphism is affecting the D2 binding region, the crystal structure 
will show us that. 
7.3 Public Health Significance 
Prostate cancer is the most common cancer among men in the United States and is the 
leading site of new cancer cases, at 25% of all cancers found in men 1.  It is second 
only to lung cancer as a cause of cancer death in the U.S.  The annual incidence of 
prostate cancer has increased by more than 30% over the last 25 years while the 
mortality rate has increased approximately 14% over the last 60 years 2.  It has been 
said that if a man lives to be 80 he will die with prostate cancer and not from it.  
Supporting this idea is the statistics that one in 30 men will develop prostate cancer 
during their life time; and one is six of those men will develop invasive prostate cancer 1.   
We have shown a direct relationship between prostate cancer and HHV-8.  We found 
that the presence of the virus results in an increase macrophage infiltrate, which is 
associated with poorer outcomes in prostate cancer 18.  Our data strongly support the 
hypothesis that HHV-8, a sexually transmitted agent, is involved in the development of 
prostate cancer.   With this new data, it is now possible to begin educational campaigns 
for the association of this sexually transmitted agent and prostate cancer.  We also 
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believe that anti-inflammatory agents may reduce the risk of prostate cancer.   The 
results of this dissertation lend support to applying anti-inflammatory agents to the 
regime of prevention of prostate cancer. 
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